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1 
PURIFICATION OF CELL MIXTURES USING 
MOLECULAR BEACONS TARGETING CELL 
SPECIFIC RNA 
2 
a pluripotent stem cell from a non-pluripotent stem cell, by 
inducing the expression of certain genes. 
Protocols for cardiomyocyte differentiation generally 
yield a heterogeneous assortment of cardiomyocytes, undif-
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This Application claims priority to U.S. Provisional 
Application No. 61/787,364 filed Mar. 15, 2013, hereby 
incorporated by reference in its entirety. 
5 ferentiated cells and non-cardiomyocytes. Obtaining enrich-
ing or purifying cardiomyocyte preparations still remains 
challenging, diminishing the clinical utility of this technol-
ogy. While the existing methods provide a level of cardio-
myocyte purity suitable for research purposes, none of these 
STATEMENT REGARDING FEDERALLY 
FUNDED RESEARCH 
10 
are suitable for clinical applications. It is known that trans-
planting a mixed population of cardiovascular cells into 
patients can lead to an adverse outcome such as teratoma 
formation or other abnormal growths. 
This invention was made with govermnent support under 
Grant Number HHSN-268201000043C awarded by the 
National Institutes of Health. The govermnent has certain 
rights in the invention. 
15 
Tyagi et al. report molecular beacons as probes that fluoresce 
upon hybridization. See Nature Biotechnology, 1996, 
14(3):303-8. 
Braam et al. report cardiomyocytes from human pluripotent 
stem cells in regenerative medicine and drug discovery. 
See Trends in Pharmacological Science, 2009, 30, 536-
545. 
INCORPORATION BY REFERENCE OF 
MATERIAL SUBMITTED AS A TEXT FILE VIA 
THE OFFICE ELECTRONIC FILING SYSTEM 
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20 Seligman et al. reports a method for isolating pluripotent/ 
multipotent stem cells from blood by using the pluripotent 
and germ-line DAZL gene as a marker. Stem Cells and 
Development, 2009, 18(9): 1263-1271. See also U.S. Pat. 
No. 6,692,965 
The Sequence Listing associated with this application is 
provided in text format in lieu of a paper copy, and is hereby 
incorporated by reference into the specification. The name of 
the text file containing the Sequence Listing is 
12147US_2016-02-04_ST25.txt. The text file is 5 KB, was 
created on Feb. 4, 2016, and is being submitted electroni-
cally via EFS-Web. 
25 King et al. report high-throughput tracking of pluripotent 
human embryonic stem cells with dual fluorescence reso-
nance energy transfer molecular beacons. See Stem Cells 
Dev, 2011, 20(3): 475-484. 
Larsson et al. report sorting live stem cells based on Sox2 
30 
mRNA expression. See PLoS ONE, 2012, 7(11): e49874. 
Elliott et al reports NKX2-5eGFP/w hESCs for isolation of 
human cardiac progenitors and cardiomyocytes. See 
Nature Methods, 2011, 8 1037-1040. 
FIELD 
35 
This disclosure is in the area of research and therapeutics. 
Uosaki et al. report purification of cardiomyocytes from 
human embryonic and induced pluripotent stem cells by 
VCAMl surface expression. See PLoS ONE, 2011, 
6:e23657. 
Dubois et al. report SIRPA is a specific cell-surface marker 
for isolating cardiomyocytes derived from human pluri-
potent stem cells. See Nature Biotechnology, 2011, 
In certain embodiments, it provides methods to assist in the 
purification of cell mixtures, e.g., cardiomyocytes, using 
molecular beacons targeting cell-type specific RNA, e.g. 
mRNA. 40 29:1011-1018. 
BACKGROUND 
Heart disease is the leading cause of death globally, 
killing 17 .3 million people worldwide. It is also the leading 45 
cause of death among men and women in the United States 
accounting for more than half of the deaths reported in the 
US in 2009. Estimates from the CDC, suggest that heart 
failure alone costs the country $34.4 billion annually in 
medication, health care, and loss in productivity. 50 
Heart failure occurs when a loss of cardiac muscle tissue 
impairs heart function leading to an inability to sufficiently 
pump oxygenated blood to other parts of the body. Cardiac 
tissue can be damaged by myocardial infarction or a heart 
attack, when the blood supply to the heart is lost resulting in 55 
the damage or death of impacted tissue. Unfortunately, these 
conditions cannot be reversed. However, cardiac regenera-
tive medicine offers promising therapies that can improve 
heart function and health. 
Yang et al. report human cardiovascular progenitor cells 
develop from a KDR+ embryonic-stem-cell-derived 
population. See Nature, 2008, 453:524-528. 
Kattman et al. report stage-specific optimization of activin/ 
nodal and bmp signaling promotes cardiac differentiation 
of mouse and human pluripotent stem cell lines. See Cell 
Stem Cell, 2011, 8:228-240. 
Bu et al. report human ISL! heart progenitors generate 
diverse multipotent cardiovascular cell lineages. See 
Nature, 2009, 460:113-117. 
Huber et al. report identification and selection of cardio-
myocytes during human embryonic stem cell differentia-
tion. See Faseb Journal, 2007, 21:2551-2563. 
Zwi et al. report cardiomyocyte differentiation of human 
induced pluripotent stem cells. Circulation, 2009, 120: 
1513-1523. 
Shiba et al. report human es-cell-derived cardiomyocytes 
electrically couple and suppress arrhythmias in injured 
hearts. Nature, 2012, 489(7415):322-5 
60 U.S. Pat. No. 8,039,259 reports buffering solutions for 
electroporation. 
Human pluripotent stems cells can now be differentiated 
into cardiomyocytes, which can be transplanted or grafted 
into patients following cardiac damage. Recent reports have 
demonstrated certain methods for the inducing the differen-
tiation of human induced pluripotent stem cells and human 
embryonic stem cells into cardiomyocytes. Another method 65 
that has garnered attention recently is induced pluripotent 
stem cell (iPSC) technology. iPSC technology differentiates 
References cited herein are not an admission of prior art. 
SUMMARY 
In certain embodiments, the disclosure relates to methods 
for purifying cell mixtures comprising, a) mixing a molecu-
US 9,493,742 B2 
3 
lar beacon, e.g., a nucleobase polymer with a double 
stranded segment, such as in a hairpin, wherein one strand 
of the double stranded segment is conjugated to a fluorescent 
dye and the other strand is conjugated a quencher, wherein 
the florescent dye and quencher are configured such that the 
fluorescent dye is quench while the nucleobase polymer is 
double stranded, wherein the nucleobase polymer comprises 
a segment that hybridizes to a target nucleic acid (e.g. RNA, 
mRNA, microRNA) with a cell mixture, under conditions 
such that the nucleobase polymer hybridizes to the nucleic 
acid in the target cell of the mixture, and does not bind all 
of the cells in the mixture, under conditions such that the 
fluorescent dye is no longer quenched by the quencher 
providing a fluorescent cell; and b) separating the fluores-
cent cell, e.g., molecular beacon bound fluorescent cardio-
myocytes, by fluorescence activated cells sorting providing 
a purified composition of fluorescent cells, e.g., cardiomyo-
cytes and a composition of non-fluorescent cells removed of 
target cells. 
In certain embodiments, the target nucleic acid is a unique 
sequence of RNA with wholly or partial single stranded 
secondary structure, e.g., within hairpin loops, bulges, inter-
nal loops, and tails. 
4 
cardiomyocytes are formed and subsequently purifying the 
mixtures of cardiomyocytes by mixing with molecular bea-
cons using methods disclosed herein. 
In further embodiments, the disclosure contemplates prior 
to after separating the fluorescent cells exposing the purified 
composition of fluorescent cells or replicated florescent cells 
to a second fluorescent molecule, e.g. fluorescently tagged 
antibody or second molecular beacon, providing a cell 
conjugated with a second fluorescent molecule and separat-
10 ing the cell conjugated with a second fluorescent molecule 
by fluorescence activated cell sorting. 
In certain embodiments, the cells mixtures are samples 
from a human subject. In certain embodiments, the cells 
mixtures are peripheral blood cells that have been enriched 
15 in CD31 + and/ or CD34 + cells. In certain embodiments, the 
cells mixtures are peripheral blood cells wherein the subject 
was prior to sampling, administered a monoclonal antibody 
against the protein CD20, such as rituximab, providing a 
peripheral blood cell mixture in which B cells have been 
20 reduced. 
In certain embodiments, the nucleobase polymers com-
prises or 15-40 nucleobases or 20-30 nucleobases with a 
fluorophore conjugated to the 5' end and a quencher at the 3' 
end, with 4-7 bps at the 5' end which are complementary to 
the bps at the 3' end. This self-complementary configuration 
induces the oligonucleotides to form a stem-loop (hairpin) 
structure so that the fluorophore and the quencher are within 
close proximity (<7, 10, or 15 nm) and fluorescence is 
quenched. Hybridization of the molecular beacons (MBs) 
In certain embodiments, the method further comprises c) 
replicating and/or further purifying the fluorescent cells to 25 
provide a substantial homogenous mixture of cells of a 
specific type. In certain embodiments, the method further 
contemplates negative selection and replicating and/or fur-
ther purifying the non-fluorescent cells to provide a sub-
stantial homogenous mixture of cells of a specific type. 30 with the target mRNA opens the hairpin structure and 
physically separates the fluorophore from the quencher, 
allowing a fluorescence signal to be emitted upon excitation. 
In certain embodiments, the disclosure contemplates that 
the target RNA is a mRNA or transcription factor RNA of a 
human stem cell-derived cardiomyocytes to provide purified 
compositions of human cardiac cells. 
In certain embodiments, the disclosure contemplates 35 
methods disclosed herein for the target RNA associated with 
neuronal cells or pancreatic ~-cells, and for isolation of other 
cell types from pluripotent stem cells or induced pluripotent 
stem cells. 
In certain embodiments, the disclosure relates to molecu-
lar beacons that target human Iroquois homeobox protein 4 
(IRX4), e.g., NCBI Reference Sequences: NM 
001278632.1, NM_001278633.1, NM_001278634.1, 
NM_001278635.1, or NM_016358.2. 
In certain embodiments, the disclosure relates to a 
molecular beacon comprising nucleic acid that targets IRX4 
In certain embodiments, the double stranded nucleic acid 
hybridizes to the target RNA in a cell of the mixture such 
that it hybridizes to less than 90, 80, 70, 60, 50, 40, 30, 25, 
20, 15, 10, 5, 4, 3, 2, 1, or 0.5% of the total cells in the 
mixture. 
In certain embodiments, the disclosure relates to using 
methods disclosed herein to provide a substantial homog-
enous mixture of cells of a specific type that is greater than 
greater than 50, 60, 70, 80, 90, or 91 % of the total cells. 
In certain embodiments, the disclosure relates to using 
methods disclosed herein to provide ventricular type car-
diomyocytes of greater than 50, 60, 70, 80, 90, or 91 % of the 
total cells. 
In further embodiments, the disclosure contemplates com-
positions and methods of generating purified composition of 
cardiomyocytes or cardiomyocyte precursor cells, e.g. ven-
tricular or atrial cardiomyocytes or cardiomyocyte precursor 
cells, prior to mixing with molecular beacons for purifica-
tion. In certain embodiments, contemplated cell mixtures 
include enriched cardiomyocytes generated from embryonic 
stem cells, e.g., derived from the inner cell mass of a 
blastocyst, an early-stage embryo, umbilical cord cells, cord 
blood, induced pluripotent stem cells of a human, bone 
marrow, peripheral blood. 
In further embodiments, the disclosure contemplates com-
positions and methods of generating purified composition of 
ventricular cardiomyocytes comprising mixing embryo bod-
ies with ascorbic acid under conditions that mixtures of 
40 having (SEQ ID NO: 1) CCCTGACGTAAACTTTATGCT 
TCAGGG or (SEQ ID N0:2) CGTAAACTTTATGCT of 
SEQ ID NO: 1, or variants thereof with greater than 50, 60, 
70, 80, 85, 90, or 95% sequence identity thereto. In certain 
embodiments, the disclosure contemplates a molecular bea-
45 con hairpin nucleobase polymer, nucleic acid, probe conju-
gated or linked to a fluorescent molecule and quencher 
having a loop sequence, e.g., (SEQ ID N0:2) 
CGTAAACTTTATGCT of SEQ ID NO: 1, of between 8 and 
25 nucleobases, or 10 to 20 nucleobases, or 11 to 17 
50 nucleobases that hybridize to a target cell sequence, and 
herein the hairpin comprises a reverse complement, or 
palindrome sequence, e.g., the (SEQ ID NO: 5) CCCTGA 
and (SEQ ID NO: 6) TCAGGG of SEQ ID NO: 1 having 6 
nucleobase pairs, or 3 to 20 nucleobase pairs, or 4 to 10 
55 nucleobase pairs, or 4 to 7 nucleobase pairs, wherein the 
loop sequence and palindrome sequence are configured such 
they will emit a fluorescence signal when hybridized to 
target mRNAs. 
In certain embodiments, the disclosure relates to a 
60 molecular beacon comprising (SEQ ID NO: 3) CCTC-
CATCTTCTTCTTCACGGAGG or (SEQ ID N0:4) ATCT-
TCTTCTTCAC of SEQ ID NO: 3 or variants thereof with 
greater than 50, 60, 70, 80, 85, 90, or 95% sequence identity 
thereto. In certain embodiments, the disclosure contemplates 
65 a molecular beacon hairpin nucleobase polymer, nucleic 
acid, probe conjugated or linked to a fluorescent molecule 
and quencher having a loop sequence, e.g., (SEQ ID N0:4) 
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ATCTTCTTCTTCAC of SEQ ID NO: 3, of between 8 and 
20 nucleobases, or 10 to 17 nucleobases, or 11 to 15 
nucleobases that hybridize to a target cell sequence, and 
herein the hairpin comprises a reverse complement, or 
palindrome sequence, e.g., the (SEQ ID NO: 7) CCTCC and 
(SEQ ID NO: 8) GGAGG of SEQ ID NO: 3 having 5 
nucleobase pairs, of 3 to 20 nucleobase pairs, or 4 to 10 
nucleobase pairs, or 4 to 7 nucleobase pairs, wherein the 
loop sequence and palindrome sequence are configured such 
they will emit a fluorescence signal when hybridized to 10 
target mRNAs. 
cence upon excitation, and wherein in the presence of 
complementary mRNA target, the emitter fluoresces upon 
excitation. 
In certain embodiments, the fluorescent emitter is Cy3 
fluorophore. In certain embodiments and the quencher is a 
BLACK HOLE QUENCHER® 2 (BHQ). In some embodi-
ments, the emitter is on the 5' end of the beacon and the 
quencher is on the 3' end of the beacon. 
In certain aspects the pluripotent cells are manimalian 
cells and in more specific embodiments, are human cells. 
In other embodiments an enriched population of cardio-
myocytes derived from pluripotent stem cells is provided, 
which is generated by a method that comprises, a) introduc-
ing a molecular beacon that targets cardiomyocyte specific 
mRNA to a mixture of differentiating pluripotent cells under 
conditions wherein the beacon hybridizes to the cardiomyo-
In certain embodiments, the disclosure contemplates mix-
ing the cell mixtures and nucleic acids by electroporation 
wherein electric pulses are employed to increase the perme- 15 
ability of the cell membrane and allow uptake of the nucleic 
acid molecules with buffering solutions that stabilize the 
cells in the electric field. 
cyte specific mRNA providing probe bound fluorescent 
cardiomyocytes, b) purifying the beacon bound fluorescent 
cardiomyocytes by fluorescence activated cells sorting, thus In certain embodiments, the buffer solution includes at 
least one saccharide or salt thereof, e.g., sodium succinate, 
mamlitol, and sodium lactobionate and/or the solution 4-6 
mM KC!, 10-20 mM MgCl2 , 5-25 mM HEPES, 50-160 mM 
Na2HP04 /NaH2P04 (at a pH of about 7-8). 
In certain embodiments, this disclosure relates to the 
purification of pluripotent stem cell (PSC) derived cardio-
myocytes from a heterogeneous mixture of differentiating 
cells using molecular beacons. Molecular beacons target a 
gene specifically expressed in cardiomyocytes and allow 
recognition of this targeting typically through fluorescence. 
This disclosure provides a method for purifying cardiomyo-
cytes that comprises, a) introducing of a molecular beacon 
that targets cardiomyocyte specific mRNA to a mixture of 
differentiating pluripotent cells under conditions where the 
beacon hybridizes to the cardiomyocyte specific mRNA, 
thus providing beacon-bound fluorescent cardiomyocytes, 
and b) purifying the beacon-bound fluorescent cardiomyo-
cytes thus providing a purified population of cardiomyo-
cytes. In some embodiments, the method further includes c) 
generating a cell line expressing said mRNA of interest by 
growing the purified population of cardiomyocytes. 
In certain aspects, the disclosure relates to a method for 
the differentiation of pluripotent stem cells into a cardio-
myocyte population that comprises a) the expansion of 
undifferentiated PSCs by culturing cells in a monolayer in 
MTESR® media, b) induction of mesodermal differentiation 
through application of bone morphogenetic protein 4 
(BMP4), ActivinA, and fibroblast growth factor 2 (FGF2) to 
hPSCs, c) induction of cardiac lineage differentiation by the 
supplementation with conditioned media, and d) continuous 
treatment with ~-adrenergic receptor agonist isoproterenol 
to generate spontaneous beating cardiomyocytes. 
20 providing a purified population of cardiomyocytes, wherein 
the cardiomyocytes in the purified population are present in 
greater than 70%, 80%, 90%, 95%, or 98% purity of the 
population of cells. 
In certain aspects this disclosure relates to a purified 
25 composition of cardiomyocytes, purified by a method that 
comprises, a) introducing a molecular beacon that targets 
cardiomyocyte specific mRNA to a mixture of differentiat-
ing pluripotent cells under conditions the beacon hybridizes 
to the cardiomyocyte specific mRNA providing beacon 
30 bound fluorescent cardiomyocytes, b) purifying the beacon 
bound fluorescent cardiomyocytes by fluorescence activated 
cell sorting thus providing a purified population of cardio-
myocytes, wherein the purified composition of cardiomyo-
cytes have more than 50% of cells staining positive for 
35 ACTN2, TNNT2, and TNNI3 by immunochemistry and 
exhibit cardiomyocyte morphology. In certain embodiments, 
at least 60%, or at least 70%, or at least 80%, or at least 90% 
or at least 95% or at least 98% stain positive. 
In other embodiments the purified composition of cardio-
40 myocytes has more than 50% of cells, or, at least 60%, or at 
least 70%, or at least 80%, or at least 90% or at least 95% 
or at least 98% of cells exhibiting expression of cardiomyo-
cyte specific genes comprising, TNNT2, MYH6, MYH7, 
and MYL2. In certain embodiments the purified composi-
45 tion of cardiomyocytes have more than 50% of cells exhib-
iting a decrease expression of genes comprising, genes 
specific to smooth muscle cells (CALPONIN), fibroblast 
(THYl), skeletal myocyte (MYOD), neural lineages (NEU-
ROD) and endothelial cells (PECAMl). In other embodi-
50 ments the purified composition of cardiomyocytes has more 
than 50% of cells that exhibit spontaneous contraction and 
rhythmic calcium oscillation. In certain embodiments, at 
least 60%, or at least 70%, or at least 80%, or at least 90% 
or at least 95% or at least 98% exhibit such contraction and 
In certain embodiments, the molecular beacon includes a 
nucleic acid sequence complementary to a cardiomyocyte 
specific mRNA and a fluorescent probe. In other embodi-
ments, the molecular beacon includes an antisense oligo-
nucleotide to a cardiomyocyte specific mRNA. In certain 
embodiments this antisense oligonucleotide is complemen-
tary to myosin heavy chain (MHCl), myosin heavy chain 2 
(MHC2), troponin T 1 (TNTl ), troponin T 2 (TNT2), 60 
troponin T 3 (TNT3) or any cardiomyocyte specific RNA 
55 oscillation. 
In certain embodiments, this disclosure relates to a kit 
comprising a molecular beacon that targets cardiomyocyte 
specific RNA, wherein the molecular beacon is an antisense 
oligonucleotide comprising a fluorescent emitter at one end, 
and quencher configured at the other, wherein the absence of 
the cell specific mRNA, the probe does not fluoresce, 
sequence. 
In some embodiments, the beacon contains a fluorescent 
emitter configured at one end and a quencher configured on 
the other, wherein in the absence of complementary 
sequences the probe folds forming a hairpin structure, caus-
ing the fluorophore to be quenched and not emit fluores-
wherein the presence of complementary cell specific mRNA 
the probe is configured to fluoresce, wherein the antisense 
oligonucleotide is complementary to myosin heavy chain 1 
65 (MHCl), myosin heavy chain 2 (MHC2), troponin T 1 
(TNTl), troponin T 2 (TNT2), troponin T 3 (TNT3) or any 
cardiomyocyte specific mRNA sequence. 
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complementary cardiomyocyte specific mRNA sequence the 
molecular beacon forms a stem loop quenching fluorescent 
signal. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. lA illustrates the structure of cardiomyocyte-specific 
molecular beacons (MBs ). A, Molecular dynamics model of 
an MB in the closed/unbound conformation. The close 
proximity of the 5' Cy3 dye and the 3' BLACK HOLE 
QUENCHER® allows for direct and FRET (Forster reso-
nance energy transfer) quenching. 
FIG. lB illustrates a molecular dynamics model of an MB 
in the open/bound conformation. The distance between the 
5' Cy3 dye and the 3' BLACK HOLE QUENCHER® 
increases greatly to prevent dye quenching. MHCl MB 
indicates an MB that targeted myosin heavy chain 6/7 
mRNA. 
FIG. 2 illustrates a strategy to enrich human pluripotent 
stem cell-derived cardiomyocytes using molecular beacons 
that target cardiomyocyte-specific mRNA. FACS indicates 
fluorescence-activated cell sorting; and qRT-PCR, quantita-
tive reverse-transcriptase polymerase chain reaction. The 
proximity of the 5' Cy3 dye and the 3' BHQ is small enough 
In certain embodiments, this disclosure relates to identi-
fying a cardioactive agent comprising contacting a cardio-
myocyte population with a test agent, wherein the cardio-
myocyte population is produced herein by methods 
comprising, a) expanding undifferentiated PSCs by culturing 5 
cells in a mono layer under in MTESR® media, b) inducing 
mesodermal differentiation through application of bone mor-
phogenetic protein 4 (BMP4), Activin A, and fibroblast 
growth factor 2 (FGF2) to PSCs, c) inducing cardiac lineage 
differentiation by the supplementation with conditioned 10 
media, and d) the continuous treatment with ~-adrenergic 
receptor agonist isoproterenol to generate spontaneous beat-
ing cardiomyocytes; e) introducing a molecular beacon that 
targets cardiomyocyte specific mRNA to a mixture of dif-
ferentiating pluripotent cells under conditions the molecular 15 
hybridizes to the cardiomyocyte specific mRNA providing 
probe bound fluorescent cardiomyocytes, f) purifying the 
probe bound fluorescent cardiomyocytes by fluorescence 
activated cells sorting (FACS) thus providing a purified 
population of cardiomyocytes, g) generating a cell line 20 
expressing said mRNA of interest by growing purified 
composition of cardiomyocytes wherein determining if the 
test agent modulates an activity or function of cardiomyo-
cytes within the population identifies the test agent as a 
cardioactive agent. 25 to allow FRET quenching. 
In other embodiments this disclosure relates to generating 
a purified cardiomyocte population for research purposes to 
be used as a model system for studying cardiac cells. In 
certain aspects the disclosure relates to isolating cardiac 
cells for experimental protocols that require the increased 30 
number or function of cardiomyocytes comprising a) intro-
ducing a molecular beacon that targets cardiomyocyte spe-
cific mRNA to a mixture of differentiating pluripotent cells 
under conditions the molecular hybridizes to the cardiomyo-
cyte specific mRNA providing probe bound fluorescent 35 
cardiomyocytes, b) purifying the probe bound fluorescent 
cardiomyocytes by fluorescence activated cells sorting 
(FACS) thus providing a purified population of cardiomyo-
cytes, c) generating a cell line expressing said mRNA of 
interest by growing purified composition of cardiomyocytes. 40 
In certain embodiments, this disclosure relates to the 
treatment of a subject suffering from the damage or death of 
cardiac cells wherein the said subject is in need of an 
increased number or function of cardiomyocytes, wherein 
the treatment comprises transplanting or grafting a cardio- 45 
myocyte population into the said subject, wherein the car-
diomyocyte population is produced by a method comprising 
a) differentiation of pluripotent stem cells into beating 
cardiomyocytes, b) the introduction of a molecular beacon 
that targets cardiomyocyte specific mRNA to a mixture of 50 
differentiating pluripotent cells under conditions the probe 
hybridizes to the cardiomyocyte specific mRNA providing 
pro be bound fluorescent cardiomyocytes, c) purifying the 
probe bound fluorescent cardiomyocytes by fluorescence 
activated cell sorting thus providing a purified population of 55 
cardiomyocytes, d) generating a cell line expressing said 
mRNA of interest by growing purified composition of 
cardiomyocytes wherein the molecular beacon is an anti-
sense oligonucleotide complementary to myosin heavy 
chain 1 (MHCl), myosin heavy chain 2 (MHC2), troponin 60 
T 1 (TNT!), troponin T 2 (TNT2), troponin T 3 (TNT3) or 
any cardiomyocyte specific mRNA sequence, wherein the 
molecular beacon comprises a fluorescent emitter at one end, 
and quencher configured at the other, wherein the molecular 
beacon hybridizes to target sequence in the presence of the 65 
complementary cardiomyocyte specific mRNA, and emits a 
fluorescent signal upon excitation, wherein the absence of 
FIG. 3A shows data on the characterization of cardio-
myocyte-specific molecular beacons (MBs). Flow cytom-
etry results of 5 different MBs designed to detect cardiac 
troponin T or myosin heavy chain 6/7 mRNAs on HL-1 
cardiomyocytes. An MB that targeted myosin heavy chain 
617 mRNA, MHCl-MB, showed the highest detection rate. 
n=3. 
FIG. 3B shows flow cytometry analysis of HL-1 cardio-
myocytes treated with random vs MHCl-MBs. Numbers 
represent percentages of MB-positive cells. n=3. CMs indi-
cates cardiomyocytes; FSC, forward scatter; MHC, myosin 
heavy chain; and TNT, troponin T. 
FIG. 4A shows data on the purification of cardiomyocytes 
from differentiating mouse embryonic stem cells (mESCs) 
with cardiomyocyte-specific molecular beacons (MBs). 
Schematic of the protocol used for differentiating mESCs to 
the cardiac lineage. EB indicates embryoid body; and ES, 
embryonic stem cell. 
FIG. 4B shows percent expression ofTnnt2 at days 4 and 
9 during mESC differentiation into cardiomyocytes; n=3. 
FIG. 4C shows immunocytochemistry results of mESC-
derived cardiomyocytes at day 9 for Tnnt2, Tnnt3, and 
Actn2. Scale bars, 20 µm. 
FIG. 4D shows flow cytometry analyses of MHCl-MB 
(an MB that targeted myosin heavy chain 6/7 mRNA) 
signals in mESC differentiation culture at day 9; n=6. FSC 
indicates forward scatter. 
FIG. 4E shows flow cytometry analysis of Tnnt2 expres-
sion in mESCs sorted with MHCl-MB and fluorescence 
activated cell sorting (FACS) at differentiation day 9; n=3. 
Numbers represent percentages of MB-positive cells (D, E). 
FIG. 4F shows FACS-sorted MHCl-MB-positive cells 
exhibited Tnnt2 and Actn2 in immunocytochemistry. Scale 
bars, 20 µm. 
FIG. 4G shows quantitative reverse-transcriptase poly-
merase chain reaction analyses showing difference in gene 
expression levels between mouse tail tip fibroblasts (MTTF) 
and presorted (PRE) and postsorted (POST) mESCs. The 
cardiomyocyte genes Tnnt2, Myh6, Myh7, and Myl2 were 
significantly enriched in postsorted cells with MHCl-MB, 
and noncardiac lineage genes (Acta2, Ddr2, Gata!, and 
Sox! 7) were substantially reduced compared with presorted 
US 9,493,742 B2 
9 
cells. The y axis represents relative mRNA expression of 
target genes to GAPDH. A. U. indicates arbitrary units. 
*P<0.05 compared with presorted group; n=3. 
FIG. SA shows data on purification of cardiomyocytes 
from differentiating human embryonic stem cells (hESCs) 5 
by cell sorting via molecular beacon (MB) and fluorescence-
activated cell sorting (FACS). Schematic of the protocol to 
differentiate human pluripotent stem cells (hPSCs) to the 
cardiac lineage. BMP4 indicates bone morphogenetic pro-
tein 4; END-2, mouse endoderm-like cells; ES, embryonic 10 
stem cell; and FGF2, basic fibroblast growth factor. 
FIG. SB shows percent expression ofTNNI3 at days 9 and 
10 
FIG. 6E shows mRNA expression levels of cardiac and 
noncardiac genes measured by quantitative reverse-tran-
scriptase polymerase chain reaction. Comparisons were 
made among human dermal fibroblast (HDF), presorted 
hiPSCs at day 13 (PRE), and MB-based FACS-sorted hiP-
SCs at day 13 (POST). They axis represents relative mRNA 
expression of target genes to GAPDH. A.U. indicates arbi-
trary units. *P<0.05 compared to presorted group; n=3. 
FIG. 6F shows time course of [Ca]2+I, measured at 
line-scan region in cell pictured and paced at 0.5 Hz by field 
stimulation. [Ca]2+ is plotted as fluorescence intensity nor-
malized to baseline (FIFO). 
FIG. 7A shows data on the transplantation of unpurified 13 determined by flow cytometry during hESC differentia-
tion into cardiomyocytes; n=3. 
FIG. SC shows flow cytometry results of MHCl-MB-
positive cells in hESC differentiation culture at day 13; n=6. 
FSC indicates forward scatter; and MHCl-MB, an MB that 
targeted myosin heavy chain 6/7 mRNA. 
15 and purified cardio-myocytes into a mouse model of acute 
myocardial infarction. Serial echocardiography demon-
strated a growing left ventricular mass at 1 week (left) and 
4 weeks (right) in mice that received unpurified mouse 
FIG. SD, Flow cytometry results showing TNNI3 expres- 20 
sion of FACS-sorted. 
embryonic stem cells (mESC)-derived cardiomyocytes. 
FIG. 7B shows images of excised hearts previously 
injected with unpurified or purified mESCderived cardio-
FIG. SE shows immunocytochemistry for TNNI3 and myocytes. 
TNNT2 on MHCl-MB-positive cells sorted from hFSC FIG. 7C shows hematoxylin-and-eosin staining of whole 
cultures. Scale bars, 20 µm. cardiac sections demonstrated infiltrative growth of hyper-
FIG. SF shows mRNA expression levels of cardiac and 25 cellular tumors surrounding the heart and protruding into the 
noncardiac genes measured by quantitative reverse-tran- cardiac lumen. Staining revealed cell derivatives of all 3 
scriptase polymerase chain reaction. Comparisons were embryonic germ layers ( endoderm, left; mesoderm, middle; 
made for human dermal fibroblast (HDF), presorted hESCs and ectoderm, right), indicating teratomas. 
at day 13 (PRE), and post-FACS-sorted cells at day 13 FIG. 7D shows improvement in cardiac function of mice 
(POST) using MHCl-MB. Cardiomyocyte genes (TNNT2, 30 transplanted with molecular beacon-purified cardiomyo-
MYH6, MYH7, and MYL2) were significantly higher in cytes derived from mESCs. Ejection fraction (EF; left) and 
sorted hESCs than in presorted hESCs and HDF. Expression fractional shortening (FS; right) were significantly higher in 
of the noncardiac lineage genes (PECAMl, CALPONIN, 
THY!, MYOD, and NEUROD) was significantly lower in the purified-cardiomyocyte-treated group than in the PBS-
sorted cells than in others. The y axis represents relative 35 treated group, as measured by echocardiography. Repeated-
mRNA expression of target genes to GAPDH. A.U. indicates measures ANO VA was used for statistical analyses. CM 
arbitrary units. *P<0.05 compared with presorted group; indicates cardiomyocytes. *P<0.05; n=5 to 10 per group. 
n=3. FIG. 8 illustrates an overall strategy to enrich mESC-
FIG. SG shows mRNA expression levels of cardiac genes derived ventricular cardiomyocytes using IRX4 MBs target-
from both MHCl-MB-positive and -negative cells measured 40 ing IRX4 mRNA. 
by quantitative reverse-transcriptase polymerase chain reac- FIG. 9A shows data on the selection of optimal ventricular 
tion. cardiomyocyte-specific IRX4 molecular beacons. Flow 
FIG. SH shows action potentials of MHCl-MB-positive cytometry results after delivering three different IRX4 MBs 
cardiomyocytes. Shown are representative configurations of designed to identify Irx4 mRNAs into mouse embryonic 
nodal (top), atrial (middle), and ventricular (bottom) action 45 fibroblasts. N=3. 
potentials. hESCs at day 13 of differentiation after applying FIG. 9B shows flow cytometric analysis of neonatal 
MHCl-MB. Numbers represent percentages of MB-positive mouse ventricular CMs treated with control MB versus two 
cells (C, D). n=3. IRX4 MBs targeting Irx4 mRNAs. N=3. 
FIG. 6A shows data on the purification of cardiomyocytes FIG. 9C shows flow cytometric analysis of HL-1 CMs 
from differentiating human induced pluripotent stem cells 50 treated with control MB versus IRX4-2-MB. N=3. The 
(hiPSCs) by cell sorting via molecular beacon (MB) and numbers in each panel represent the percentages of fluores-
fluorescence-activated cell sorting (FACS). Schematic of the cent cells. 
protocol to differentiate hiPSCs to the cardiac lineage. FIG. lOA shows data on the characterization of general 
BMP4 indicates bone morphogenetic protein 4; END-2, and ventricular cardiomyocytes differentiated from mESCs. 
mouse endoderm-like cells; ES, embryonic stem cells; and 55 A schematic of the protocol to differentiate mESCs to the 
FGF2, basic fibroblast growth factor. cardiac lineage. ESCs indicate mouse embryonic stem cells; 
FIG. 6B shows percent expression ofTNNI3 at days 9 and and EB, embryoid body. 
13 during hiPSC differentiation into cardiomyocytes deter- FIG. lOB shows expression profiles of the CM-specific 
mined by flow cytometry; n=3. genes (Tnnt2 and Myh6/7) and chamber-specific CM genes 
FIG. 6C shows flow cytometric analysis of MHCl-MB 60 (Myl7, Myl2 and Irx4) during cardiomyocyte differentiation 
signals in hiPSC differentiation culture at day 13; n=6. from mESCs. Y axis represents relative mRNA expression 
MHCl-MB indicates an MB that targeted myosin heavy of target genes to GAPDH. N=3. 
chain 6/7 mRNA. FIG. llA illustrates and shows data on the purification of 
FIG. 6D shows flow cytometric results showing TNNI3 ventricular cardiomyocytes from differentiating mESCs 
expression of FA CS-sorted hiPSCs at day 13 of differentia- 65 through IRX4-2 MBs. A schematic illustrating the time point 
tion after applying MHCl-MB. Numbers represent percent- of delivering IRX4-2 MBs at day 18 in differentiating mESC 
ages of MB-positive cells (C, D). n=3. cultures. 
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FIG. llB shows flow cytometry results of IRX4-2 MB-
positive cells in mESC differentiation culture at day 18. 
N=6. 
FIG. llC shows flow cytometry results showing Tnnt2 
and Myl2 expression in mESC-derived ventricular cardio-
myocytes which were FACS-sorted after delivering IRX4-2 
MBs at day 18. N=3. 
FIG. 12A shows electrophysiological characteristics of 
IRX4-2 MB-purified ventricular cardiomyocytes Action 
potentials of the IRX4-2 MB-positive and -negative cells. 
Shown are representative configurations of the action poten-
tials from IRX4-2 MB-positive (left) and negative cells 
(right). 
12 
embodiments only, and is not intended to be limiting, since 
the scope of the present disclosure will be limited only by 
the appended claims. 
Unless defined otherwise, all technical and scientific 
terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which this 
disclosure belongs. 
All references, publications, or information available on 
electronic databases are hereby incorporated by reference in 
10 their entirety. 
It must be noted that, as used in the specification and the 
FIG. 12B shows half action potential duration (APD50) 15 
and upstroke slope of IRX4-2 MB-positive and negative 
cells. Action potentials were measured from 50 cells from 
either IRX4-2 MB-positive or negative cells. 
appended claims, the singular forms "a," "an," and "the" 
include plural referents unless the context clearly dictates 
otherwise. Thus, for example, reference to "a support" 
includes a plurality of supports. 
The term "fluorescence-activated cell sorting" refers to a 
method of sorting a mixture of cells into two or more areas, 
typically one cell at a time, based upon the fluorescent 
characteristics of each cell, a respectively applied electrical 
charge, and separation by movement through an electrostatic 
FIG. 12C shows the percentages of the action potential 
types recorded from IRX4-2 MB positive and -negative 20 
cells. A-like: atrial-like AP, V-like: ventricular-like AP. 
FIG. 12D shows calcium transients in IRX4-2 MB-posi-
tive ventricular CMs sorted from mESCs. Upper panel is a 
line scans of spontaneous calcium transients recorded across 
a beating cell, purple to yellow color gradient indicates 25 
increasing calcium. Lower panel demonstrates average cal-
cium transient measured from line scan where fluorescence 
field. Typically, a vibrating mechanism causes a stream of 
cells to break into individual droplets. Just prior to droplet 
formation, cells in a fluid pass through an area for measuring 
fluorescence of the cell. An electrical charging mechanism is 
configured at the point where the stream breaks into drop-
lets. Based on the fluorescence intensity measurement, a 
respective electrical charge is imposed on the droplet as it 
breaks from the stream. The charged droplets then move 
is normalized to baseline at time 0. 
FIG. 13 shows data on characterization of purified ven-
tricular CMs through IRX4-2 MBs mRNA expression of 
cardiac and non-cardiac genes in IRX4-2 MB-positive and 
negative cells measured by qRT-PCR. Y axis represents 
relative mRNA expression of target genes to GAPDH. 
*P<0.05 compared to pre-sorted group. N=3. 
FIG. 14A illustrates molecular beacon structure and con-
trol molecular beacons. A schematic of a molecular beacon 
in a stem-loop hairpin conformation. The stem brings the 5' 
dye and 3' quencher together to quench the fluorescence 
signal. The loop region with 15-30 base pairs is comple-
mentary to the target sequence of specific mRNA thus 
providing specificity. 
FIG. 14B shows a schematic depicting a molecular bea-
con in an open conformation after hybridizing to its comple-
mentary target mRNA sequence. Hybridization induces a 
conformational change that separates the fluorophore from 
the quencher, resulting in a > 10-fold increase in fluorescence 
signal. 
FIG. 14C shows a schematic of a positive control molecu-
lar beacon with a fluorescent dye attached to both the 5' and 
3' ends, thus is constitutively fluorescent. This probe is used 
to determine ifMBs can be delivered into different cell types 
efficiently and uniformly. 
FIG. 14D shows a schematic depicting a specific negative 
control beacon. The four mutated bases should prohibit 
hybridization of the probe to the target region of specific 
mRNA. When delivered into HL-1 as positive control cells, 
this control beacon should yield very low background sig-
nal, confirming the MB specificity. 
DETAILED DESCRIPTION 
Before the present disclosure is described in greater detail, 
it is to be understood that this disclosure is not limited to 
particular embodiments described, and as such may, of 
course, vary. It is also to be understood that the terminology 
used herein is for the purpose of describing particular 
30 through an electrostatic deflection system that diverts drop-
lets into areas based upon their relative charge. In some 
systems, the charge is applied directly to the stream, and the 
droplet breaking off retains charge of the same sign as the 
35 stream. The stream is then returned to neutral after the 
droplet breaks off. In other systems, a charge is provided on 
a conduit inducing an opposite charge on the droplet. 
The term "nucleobase polymer" refers to a polymer 
comprising nitrogen containing aromatic or heterocyclic 
40 bases that bind to naturally occurring nucleic acids through 
hydrogen bonding otherwise known as base pairing. A 
typical nucleobase polymer is a nucleic acid, RNA, DNA, 
combination, or chemically modified form thereof. A nucleic 
acid may be single or double stranded or both, e.g., they may 
45 contain overhangs. Nucleobase polymers may contain 
wholly or partially naturally occurring or synthetically 
modified bases and backbones. In certain embodiments, a 
nucleobase polymer need not be entirely complementary, 
e.g., may contain one or more insertions, deletions, or be in 
50 a hairpin structure provided that there is sufficient selective 
binding. Cytosine may be unmethylated or methylated, e.g., 
5-methylcytosine. 
In certain embodiments, a nucleobase polymer disclosed 
herein comprises monomers of phosphodiester, phosphoro-
55 thioate, methylphosphonate, phosphorodiamidate, pipera-
zine phosphorodiamidate, ribose, 2'-0-methyl ribose, 2'-0-
methoxyethyl ribose, 2'-fluororibose, deoxyribose, 
l-(hydroxymethyl)-2,5-dioxabicyclo[2.2.1]heptan-7-ol, 
P-(2-(hydroxymethy l)morpholino )-N,N-dimethylphospho-
60 namidate, morpholin-2-ylmethanol, (2-(hydroxymethyl) 
morpholino) (piperazin-1-yl)phosphinate, or peptide nucleic 
acids or combinations thereof. 
In certain embodiments, the nucleobase polymers are 8 to 
25 base oligomers that mimic DNA or RNA. Many nucle-
65 abase polymers differ from native RNA or DNA in the 
chemical structure that links the four common bases. For 
example, a RNA may be modified wholly or partially to 
US 9,493,742 B2 
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contain phosphorothioates instead of phosphodiester link-
ages. Nucleobase polymers that contain phosphorothioates 
may hybridize to RNA. 
14 
In certain embodiments, nucleobase polymers are con-
templated to comprise peptide nucleic acids (PNAs). One 
example of a peptide nucleic acid is one that has 2-amino-
ethyl glycine linkages or similar analoges in place of the 
regular phosphodiester backbone. Other examples include 
d-lysPNA, argPNA, alternating units of 2-aminocyclopen-
tanoic acid and pyrrolidine-2-carboxylic acid (pyrPNA). See 
Nielson, Chem & Biodiversity, 2010, 7:786. 
In certain embodiments, nucleobase polymers are con-
templated to comprise non-natural nucleobases such as, but 
not limited to, pseudoisocytosine as a substitute for cytosine, 
diaminopurine as a substitute for adenine, bicyclic thymine 
analogue (7Cl-bT), thiouracil, or combinations thereof. 
need to find a surface protein specifically expressed on the 
target cell. Heyduk et al., Molecular beacons for detecting 
DNA binding proteins, Nature Biotechnology, 2002, 20: 171-
176; Rhee et al., Target accessibility and signal specificity in 
live-cell detection of BMP-4 mRNA using molecular bea-
cons, Nucleic Acids Research 2008; 36:e30; Van Hoof et al., 
Identification of cell surface proteins for antibody-based 
selection of human embryonic stem cell-derived cardiomyo-
cytes, Journal of Proteome Research, 2010, 9:1610-1618, 
10 
and Kelly et al., Cell-surface markers for the isolation of 
pancreatic cell types derived from human embryonic stem 
cells, Nature Biotechnology, 2011,29:750-756. Thus, this 
approach can be more broadly applied to other cell types 
In certain embodiments, nucleobase polymers are con-
templated to comprise phosphorodiamidate morpholino oli-
gomers (PMO). In certain embodiments, the nucleobase 
polymer comprises monomers of (2-(hydroxymethyl)mor-
pholino )(piperazin-1-yl)phosphinate. 
15 regardless of the availability of specific surface proteins or 
antibodies. This is a desirable method for cell purification, as 
one of the main hurdles to using hPSCs in regenerative 
medicine is the lack of proper purification methods. Kelly et 
al., Cell-surface markers for the isolation of pancreatic cell 
20 types derived from human embryonic stem cells, Nature 
Biotechnology, 2011, 29:750-756. 
Purification of Pluripotent Stem Cell-Derived Cardiomyo-
cytes Using Molecular Beacons 
In certain embodiments this disclosure relates to methods 
In some embodiments, this technique may be more widely 
applied to neuronal cells or islet cells that are indispensable 
for cell-based therapy but lack known surface markers, and 
of transplanting or grafting purified stem cell derived car-
diomyocytes into a host that require the increased number or 
function of healthy cardiomyocytes. In other embodiments 
this disclosure relates to the transplanting or grafting of stem 
cell derived cardiomyocytes into a host that suffer from loss 
25 will allow homogenous cell populations to be used for drug 
discovery and disease modeling which have long awaited 
purified human primary cells. Another benefit of the molecu-
lar beacon-based isolation is its applicability to cells from 
other species as shown for mESCs, facilitating research with 
30 purified cells derived from mouse or rat PSCs. In terms of 
the side effects profile, as molecular beacons usually degrade 
within an hour, cell viability or cell fate change is not a 
or damage of cardiac tissue. In other aspects, this disclosure 
relates to the transplanting or grafting of purified stem cell 
derived cardiomyocytes into patients that suffer from heart 
disease including but not limited to heart failure, heart 
attack, coronary artery disease, cardiomyopathy, restrictive 
cardiomyopathy, or hypertrophic cardiomyopathy. In other 35 
aspects, this disclosure relates to a method that provides the 
purification of stem cell derived cardiomyocytes for research 
that requires the increased number of function of purified 
cardiomyocytes. 
In certain aspects, this disclosure relates to a very efficient 40 
and specific method for purifying cardiomyocytes from 
differentiating mouse and human pluripotent stem cells by 
directly targeting mRNA of cardiomyocyte-specific genes 
using a molecular beacon followed by fluorescent activated 
cell sorting. The method provided herein purifies cardio- 45 
myocytes to a yield of greater than 50%, such as at least 
60%, at least 65%, at last 70%, at least 75%, at least 80%, 
senous concern. 
Methods 
The disclosure provides methods for purifying pluripotent 
stem cell-derived cardiomyocytes using molecular beacons 
that are designed to target cardiomyocyte specific-mRNA. 
In certain aspects, this disclosure provides a method of 
generating purified composition of cardiomyocytes that can 
be used as a clinical therapy for patients with cardiac 
damage or as a research tool. Accordingly this disclosure 
describes a method of a) introducing a molecular beacon that 
targets cardiomyocyte specific mRNA to a mixture of dif-
ferentiating pluripotent cells under conditions the molecular 
hybridizes to the cardiomyocyte specific mRNA providing 
probe bound fluorescent cardiomyocytes, b) purifying the 
probe bound fluorescent cardiomyocytes by fluorescence 
activated cells sorting (FACS) thus providing a purified 
population of cardiomyocytes, c) generating a cell line 
at least 85%, at least 90%, at least 95%, at least 96%, at least 
97%, at least 98% or at least 99% purity of cardiomyocytes 
from differentiating PSCs. 50 expressing said mRNA of interest by growing purified 
composition of cardiomyocytes. The molecular beacon method has distinct advantages for 
isolating enriched populations ofhPSC-derived cardiomyo-
cytes. By enabling detection of specific sequences in the 
genes that are exclusively expressed in cardiomyocytes, the 
molecular beacon-based cell isolation technique minimizes 55 
the potential of contamination by other cells, which is a main 
concern in the current isolation method. Elliott et al., Nkx2-
5egfp/w hESCs for isolation of human cardiac progenitors 
and cardiomyocytes, Nature Methods, 2011, 8:1037-1040; 
Dubois et al., SIRPA is a specific cell-surface marker for 60 
isolating cardiomyocytes derived from human pluripotent 
stem cells, Nature Biotechnology, 2011, 29: 1011-1018; 
Kamp et al., Recognizing heart cells in a crowd, Nature 
Methods, 2011, 8:1013-1016; and Mummery et al., Sorting 
cardiomyocytes: A simple solution after all? Nature Meth- 65 
ods, 2010, 7:40-42. Since molecular beacons can bind 
intracellular mRNA through delivery techniques there is no 
In certain embodiments, the disclosure provides a method 
for the differentiation of pluripotent stem cells into a car-
diomyocyte population that comprises a) expanding undif-
ferentiated pluripotent stem cells by culturing cells in a 
mono layer in MTESR® media, b) inducing mesodermal 
differentiation through application of bone morphogenetic 
protein 4 (BMP4), Activin A, and fibroblast growth factor 2 
(FGF2) to hPSCs, c) inducing of cardiac lineage differen-
tiation by the supplementation with conditioned media, and 
d) continuous treatment with ~-adrenergic receptor agonist 
isoproterenol to generate spontaneous beating cardiomyo-
cytes. In other embodiments, this disclosure provides a 
method of differentiating pluripotent stem cells into cardio-
myocytes that can be used for differentiation of manimalian 
induced pluripotent stem cells or embryonic stem cells into 
cardiomyocytes. 
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In certain aspects, this disclosure provides a method for 
selecting cardiomyocyte specific mRNA as potential targets 
16 
of the molecular beacon wherein, known structural cardiac 
genes were selected comprising, myosin heavy chain 1 
(MHCl), myosin heavy chain 2 (MHC2), troponin T 1 
(TNT!), troponin T 2 (TNT2), troponin T 3 (TNT3) 
wherein, reverse transcriptase (qRT-PCR) analysis was per-
formed on extracted mRNA to determine if target mRNA 
would be detectable by molecular beacons. Detection of 
each cardiomyocyte specific mRNA was depicted in FIG. 5. 10 
In other embodiments, this disclosure provides a method 
that selects the MHC-1 gene as the optimal cardiomyocyte 
specific mRNA target. 
myocyte (MYOD), neural lineages (NEUROD), and EC 
(PECAMl ). In yet other aspects, this disclosure provides a 
method for validating the purity of the isolated cardiomyo-
cyte composition wherein more than 50% of the cells exhibit 
spontaneous beating and rhythmic calcium oscillation. The 
embodiments of this disclosure provides a method that 
purified pluripotent stem cell derived cardiomyocytes 
exhibit a purity of cardiomyocytes greater than 70%, 80%, 
90%, 95% or 98% homogeneity. 
In other aspects, this disclosure provides a method of 
generating a purified composition of cardiomyocytes that 
can be used in the identification of a cardioactive agent 
comprising a) introducing a molecular beacon that targets 
cardiomyocyte specific mRNA to a mixture of differentiat-In certain embodiments this disclosure provides a method 
of synthesizing the molecular beacons that target the car-
diomyocyte specific mRNA comprising designing an oligo-
nucleotide sequence of that is complementary to the specific 
target mRNA, wherein the complementary target sequence 
is flanked by an additional sequence on each side of the 
oligonucleotide that base pair with each other. In other 
embodiments, this disclosure provides a method for design-
ing the molecular beacon wherein the oligonucleotide is 
configured with a fluorophore on one end, and a fluorescent 
quencher on the opposite end of the oligonucleotide. This 
disclosure provides a method for designing the molecular 
beacon wherein, the oligonucleotide is configured with a 
Cy3 fluorophore on the 5' end and a BLACK HOLE 
QUENCHER® 2 (BHQ) on the 3'. 
In certain embodiments, this disclosure provides a method 
of introducing the molecular beacons into the mixed popu-
lation of cardiomyocytes and differentiating pluripotent 
stem cells that comprises Streptolysin 0, LIPO-
FECTAMINE®2000, LULLABY®, NUCLEOFEC-
TION®, electroporation, and microinjection. In other 
aspects, this disclosure provides methods for the delivery of 
the molecular beacons into the differentiating cells by 
NUCLEOFECTION®. 
Certain aspects of this disclosure provides a method 
wherein, upon the introduction of the molecular beacons to 
a mixture of cardiomyocytes and pluripotent stem cells, the 
beacon hybridizes to the complementary mRNA target 
sequence within cardiomyocytes, wherein upon excitation 
these hybridized molecular beacons emit a fluorescent sig-
nal. In other aspects, this disclosure provides a method 
where in the absence of a complementary cardiomyocyte 
mRNA the molecular beacon forms a stem loop, quenching 
the fluorescent signal of the fluorophore. 
In other embodiments, this disclosure provides a method 
for isolating cardiomyocytes from a mixed population of 
differentiating cells where molecular beacons that have 
hybridized to target mRNA sequences emit a fluorescent 
signal, allowing for the isolation and purification of these 
cardiomyocytes using fluorescence activated cell sorting, 
hence a purified composition of cardiomyocytes. 
15 ing pluripotent cells under conditions the molecular hybrid-
izes to the cardiomyocyte specific mRNA providing probe 
bound fluorescent cardiomyocytes, b) purifying the probe 
bound fluorescent cardiomyocytes by fluorescence activated 
cells sorting (FACS) thus providing a purified population of 
20 cardiomyocytes, c) generating a cell line expressing said 
mRNA of interest by growing purified composition of 
cardiomyocytes d) contacting the purified cardiomyocyte 
population with a test agent; and e) determining if the test 
agent modulates an activity or function of purified cardio-
25 myocytes within the population thus identifying the test 
agent as a cardioactive agent. 
In other embodiments this disclosure provides a method 
for generating a purified cardiomyocte population for 
research purposes to be used as a model system for studying 
30 cardiac cells. This disclosure provides a method of isolating 
cardiac cells for experimental protocols that require the 
increased number or function of cardiomyocytes comprising 
a) introducing a molecular beacon that targets cardiomyo-
cyte specific mRNA to a mixture of differentiating pluripo-
35 tent cells under conditions the molecular hybridizes to the 
cardiomyocyte specific mRNA providing probe bound fluo-
rescent cardiomyocytes, b) purifying the probe bound fluo-
rescent cardiomyocytes by fluorescence activated cells sort-
ing (FACS) thus providing a purified population of 
40 cardiomyocytes, c) generating a cell line expressing said 
mRNA of interest by growing purified composition of 
cardiomyocytes. 
In other embodiments this disclosure provides a method 
for generating a purified cardiomyocte population for 
45 patients that suffer damage or death of cardiac cells. This 
disclosure provides a method of isolating cardiac cells to 
assist in the treatment of patients in need of increased 
numbers or function of cardiomyocytes comprising a) intro-
ducing a molecular beacon that targets cardiomyocyte spe-
50 cific mRNA to a mixture of differentiating pluripotent cells 
under conditions the molecular hybridizes to the cardiomyo-
cyte specific mRNA providing probe bound fluorescent 
cardiomyocytes, b) purifying the probe bound fluorescent 
cardiomyocytes by fluorescence activated cells sorting 
55 (FACS) thus providing a purified population of cardiomyo-
cytes, c) generating a cell line expressing said mRNA of 
interest by growing purified composition of cardiomyocytes 
d) administering, transplanting or grafting the purified com-
position of cardiomyocytes generated by said purification 
In certain embodiments, this disclosure provides a method 
for verifying the purity of the isolated cardiomyocyte popu-
lation wherein more than 50% of the cells stain positive for 
cardiomyocyte markers ACTN2, TNNT2, and TNNI3 by 
immunohistochemistry and also exhibit cardiomyocyte mor-
phology. In other embodiments, this disclosure provides a 
method for confirming the homogeneity of the purified 
cardiomyocyte population by examining the expression 
level of specific genes, wherein more than 50% of the cells 
exhibit an increased expression of cardiomyocyte specific 
genes, TNNT2, MYH6, MYH7, MYL2, and a marked 65 
decrease in the expression of genes specific for smooth 
muscle cells (CALPONIN), fibroblast (THY!), skeletal 
60 method into patients. 
Molecular Beacons 
Generally, the MB includes a nucleic acid that binds to a 
cardiomyocyte-specific mRNA, and includes at least one 
fluorophore and at least one quencher. In some embodi-
ments, the nucleic acid binds to at least a portion of a 
cardiomycoyte specific mRNA. In some embodiments, the 
cardiomyocyte-specific mRNA is selected from the group 
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consisting of: myosin heavy chain 1 (MHCl ), myosin heavy 
chain 2 (MHC2), troponin T 1 (TNTl ), troponin T 2 (TNT2), 
troponin T 3 (TNT3) wherein, reverse transcriptase (qRT-
PCR) confirms that genes will be detectable by the molecu-
lar beacon. In other embodiments, the nucleic acid binds to 5 
at least a portion of an mRNA selected from the group 
comprising of genes encoding myosin heavy chain 1 
(MHCl ), myosin heavy chain 2 (MHC2), troponin T 1 (TNT 
1), troponin T 2 (TNT2), troponin T 3 (TNT3), ACTN2, and 
TNNI3. In still further embodiments, the nucleic acid binds 10 
to at least a portion of an mRNA selected from MYH6, 
MYH7, and MYL2. In specific embodiments, the nucleic 
acid binds to at least MHCl. In some embodiments, the 
nucleic acid includes at least 5, or at least 10, or at least 15, 
or at least 20, or at least 25, or at least 30, or at least 35 or 15 
at least 40 base pairs that bind to a cardiomycyte-specific 
mRNA. 
18 
myosin I, a-Actin (ACTC), Colligin, HSPl 7, HSP90, Lac-
tate dehydrogenase, a-Enolase 1 (ENOl), Voltage-depen-
dent anion channel 1 (VDAC-1), RAB-7, Protein 
phosphatase 1, regulatory (inhibitor) subunit (PPPl R), 
RSU-1, Makorin I, CGI 146 protein, Crystallin aB, Exos-
tose 2 (EXT2), Elongation factor eiF 4A, Protein phos-
phatase 1, catalytic subunit-beta isoform (PPPl CB), and 
Glutamic oxaloacetic transaminase (GOTl). 
Methods of Use 
In certain aspects, this disclosure provides a method for 
generating a purified composition of cardiomyocytes for 
patients that suffer damage or death of cardiac tissue. This 
disclosure provides a method of isolating cardiac cells to 
assist in the treatment of patients suffering from heart 
disease including but not limited to heart failure, heart 
attack, coronary artery disease, cardiomyopathy, restrictive 
cardiomyopathy, or hypertrophic cardiomyopathy, wherein 
the patient is in need of an increased number or function of 
cardiomyocytes comprising a) introducing a molecular bea-
In certain embodiments the complementary cardiomy-
cyte-specific mRNA sequence is flanked by a stem loop 
sequence that base pairs in the absence of a target sequence. 
This flanking stem loop nucleic acid sequence can be at 4, 
or at least 5, or at least 6 base pairs long. 
In some embodiments, the molecular beacon includes at 
least one fluorophore. In other embodiments, the MB 
includes at least two fluorophores. In such embodiments, the 
two or more fluorophores can be in close proximity, and in 
some embodiments excitation of one fluorophore can lead to 
excitation of a second or further fluorophores. Examples of 
fluorophores include but are not limited to Cy2, Cy3, Cy3B, 
Cy3.5, Cy5, Cy5.5, Cy7, FAM, 6-FAM, Fluorescein, JOE, 
TET, HEX, TRITC, TEXAS RED®, X-Rhodamine, Lissa-
mine Rhodamine B, Allophycocyanin (APC), BODIPY-FL, 
FluorX, TruRed, PerCP, Red 613, R-Phycoerythrin (PE), 
NBD, Lucifer Yellow, Pacific Orange, Pacific Blue, Cascade 
Blue, Methoxycoumarin, Aminocoumarin, and Hydroxy-
coumarin. In some embodiments the fluorophore is attached 
to the MB adjacent to the stem loop sequence. 
20 con that targets cardiomyocyte specific mRNA to a mixture 
of differentiating pluripotent cells under conditions the 
molecular hybridizes to the cardiomyocyte specific mRNA 
providing probe bound fluorescent cardiomyocytes, b) puri-
fying the probe bound fluorescent cardiomyocytes by fluo-
In some embodiments, the molecular beacon includes at 
least one quencher. In some embodiments, the quencher is a 
non-fluorescent quencher including but not limited to a 
BLACK HOLE QUENCHER® (BHQ), Eclipse Dark 
Quencher (DQ), IOWA Black (IWB), DABCYL, and 
TAMRA. In certain embodiments, the quencher is at least 14 
nucleic acids away from the fluorophores. In some embodi-
ments the quencher is attached to the MB adjacent to the 
stem loop sequence. 
Cardiomyocyte Specific mRNAs 
25 rescence activated cells sorting (FACS) thus providing a 
purified population of cardiomyocytes, c) generating a cell 
line expressing said mRNA of interest by growing purified 
composition of cardiomyocytes d) administering, transplant-
ing or grafting the purified composition of cardiomyocytes 
30 generated by said purification method into patients. 
In certain embodiments this disclosure provides a method 
for producing a purified composition of cardiac cells for 
research purposes to be used as a model system for studying 
cardiomyocytes. This disclosure provides a method of iso-
35 lating cardiac cells for experimental protocols that require 
the increased number or function of cardiomyocytes com-
prising a) introducing a molecular beacon that targets car-
diomyocyte specific mRNA to a mixture of differentiating 
pluripotent cells under conditions the molecular hybridizes 
40 to the cardiomyocyte specific mRNA providing probe bound 
fluorescent cardiomyocytes, b) purifying the probe bound 
fluorescent cardiomyocytes by fluorescence activated cells 
sorting (FACS) thus providing a purified population of 
cardiomyocytes, c) generating a cell line expressing said 
45 mRNA of interest by growing purified composition of 
cardiomyocytes. 
In other embodiments, this disclosure provides a method 
that can be used for research purposes to examine the 
function and activity of the purified cardiomyocyte compo-
50 sition within a host. In certain embodiments this method 
In some embodiments, this disclosure provides cardio-
myocyte specific mRNA that can be targeted by molecular 
beacons, and used in the purification of stem cell derived 
cardiomyocytes. In certain embodiments cardiomyocyte 
specific mRNA targets can be selected and confirmed by 
using reverse transcriptase (qRT-PCR) to ensure that genes 
will be detectable by the molecular beacon. In certain 
embodiments, a MB hybridizes to a portion of the cardio- 55 
myocyte specific mRNA, and upon excitation fluoresces, 
marking cardiomyocytes with this specific mRNA for selec-
tion and further purification. The cardiomyocyte specific 
mRNA are genes that are highly expressed in cardiomyo-
cytes in comparison to expression levels of these genes in 60 
other cell types. In some embodiments, the cardiomyocyte-
specific mRNA is selected from a group comprising myosin 
heavy chain 1 (MHCl), myosin heavy chain 2 (MHC2), 
troponin T 1 (TNTl), troponin T 2 (TNT2), troponin T 3 
(TNT3) ACTN2, TNNT2, and TNNI3, MYH6, MYH7, 65 
Myosin light chain 2 (MYL 2), Myosin light chain 2a (MYL 
2a), Myosin light chain polypeptide 4 (MYL 4), a-Tropo-
comprises a) introducing a molecular beacon that targets 
cardiomyocyte specific mRNA to a mixture of differentiat-
ing pluripotent cells under conditions the molecular hybrid-
izes to the cardiomyocyte specific mRNA providing probe 
bound fluorescent cardiomyocytes, b) purifying the probe 
bound fluorescent cardiomyocytes by fluorescence activated 
cells sorting (FACS) thus providing a purified population of 
cardiomyocytes, c) generating a cell line expressing said 
mRNA of interest by growing purified composition of 
cardiomyocytes d) transplanting or grafting the purified 
cardiomyocyte population into the desired mammalian host 
and examining cardiomyocyte function within the host. 
Kits 
The disclosure provides kits for carrying out any of the 
methods described herein. Kits of the disclosure may com-
prise at least one molecular beacon specific for cardiomyo-
cyte specific mRNA, and may further include instructions 
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for carrying out a method described herein. Kits may also 
comprise oligonucleotides for the corresponding cardiomyo-
cyte specific target gene for qRT-PCR analysis to ensure that 
said gene will be detectable by molecular beacons provided 
therein. 
In certain embodiment, the disclosure provides kits for 
purifying pluripotent stem cell derived cardiomyocytes from 
20 
beacons, steps to isolate cardiomyocytes with bound 
molecular beacons, steps n for assaying efficiency of puri-
fication, steps for validating purity, and interpretation of 
results. 
Instructions supplied in the kits of the disclosure are 
typically written instructions on a label or package insert 
(e.g., a paper sheet included in the kit), but machine-
readable instructions (e.g., instructions carried on a mag-
netic or optical storage disk) are also acceptable. In certain 
a mixed population of differentiating pluripotent cells 
including at least one molecular beacon that targets a car-
diomyocyte specific mRNA, where the molecular beacon is 
from a group consisting of myosin heavy chain 1 (MHCl ), 
myosin heavy chain 2 (MHC2), troponin T 1 (TNT!), 
troponin T 2 (TNT2), troponin T 3 (TNT3) or any cardio-
myocyte specific mRNA sequence and instructions for car-
rying out a method for the purification of pluripotent stem 
cell derived cardiomyocytes described herein. 
10 embodiments, machine-readable instructions comprise soft-
ware for a progranimable digital computer for comparing the 
measured values obtained using the reagents included in the 
kit. 
Systems for Detecting and Sorting Cardiomyocytes with 
15 Molecular Beacon Bound mRNA 
In some other aspect, the disclosure provides kits for 
purifying pluripotent stem cell derived cardiomyocytes from 
a mixed population of differentiating pluripotent cells 
including at least one reagent specific for MHC-1; and 20 
instructions for carrying out a method for the purification of 
stem cell derived cardiomyocytes described herein. 
In a further aspect, the disclosure provides kits for puri-
fying pluripotent stem cell derived cardiomyocytes from a 
mixed population of differentiating pluripotent cells includ- 25 
ing at least one reagent specific for MHC-1, at least one 
reagent specific for MHC-2, at least one reagent specific for 
TNT!, at least one reagent specific for TNT2, one reagent 
specific for TNT3 and instructions for carrying out a method 
for the purification of pluripotent stem cell derived cardio- 30 
myocytes described herein. 
In further examples of kits, the reagent specific for the 
cardiomyocyte specific mRNA can be oligonucleotides that 
are specific for the said mRNA target. In further examples of 
kits, the reagent specific for the cardiomyocyte specific 35 
mRNA can be a molecular beacon. In further examples of 
kits the reagent specific for the cardiomyocyte specific 
mRNA can be a fluorescent probes. 
More commonly, kits of the disclosure comprise at least 
one molecular beacon that targets a cardiomyocyte specific 40 
mRNA, where the reagent is particular to the cardiomyocyte 
specific mRNA. In some embodiments, kits comprise at 
least 2, at least 3, at least 4, or at least 5, reagents specific 
for a molecular beacon or a cardiomyocyte specific mRNA 
target. In some embodiments, the reagent is specific for a 45 
cardiomyocyte mRNA target. In certain embodiments, the 
reagents are specific for myosin heavy chain 1 (MHCl), 
myosin heavy chain 2 (MHC2), troponin T 1 (TNT!), 
troponin T 2 (TNT2), troponin T 3 (TNT3). 
In certain embodiments, the methods may be imple-
mented by computers, systems, or stored on a computer-
readable storage medium as instructions for detecting car-
diomyocytes with molecular beacon bound mRNA. 
In some embodiments, the disclosure relates to a system. 
The system may include a computer having a processor 
configured to perform the methods of the disclosure. The 
system may also include or may communicate with a laser, 
electronic detection apparatus, fluorescent camera, or other 
device that can measure light or a change in current of an 
electrode or system configured to subject a sample to testing 
device. 
In some embodiments, the system may include a com-
puter having a processor configured to perform the methods 
of the disclosure. In certain embodiments, the method con-
templates recording measurements on a computer readable 
medium as data. In certain embodiments the disclosure, 
contemplates reporting purification results to a medical 
professional, researcher or a representative thereof. In cer-
tain embodiments, the disclosure contemplates transferring 
recorded data over the internet from a lab to a computer in 
a medical or research facility. 
In some embodiments, the method further comprises 
outputting quantification results. In some embodiments, the 
method may further comprise recording the detected 
changes on a computer-readable medium through a visual 
device such as a camera or video recorder. In certain 
embodiments, the disclosure contemplates calculating fluo-
rescent intensity. 
In some embodiments, the yield and purity of cardiomyo-
cytes may be outputted from a visual device through fluo-
rescence. In some embodiments, the outputting may include 
displaying, printing, storing, and/or transmitting the mea-
sured fluorescence levels. In some embodiments, the mea-
sured fluorescence may be transmitted to another system, 
server and/or storage device for the printing, displaying 
and/or storing. 
Kits comprising a single reagent specific for a molecular 50 
beacon or cardiomyocyte specific mRNA target will gener-
ally have the reagent enclosed in a container (e.g., a vial, 
ampoule, or other suitable storage container). Likewise, kits 
including more than one reagent may also have the reagents 
The methods of the disclosure are not limited to the steps 
described herein. The steps may be individually modified or 
55 omitted, as well as additional steps may be added. in containers (separately or in a mixture). 
In some embodiments, the cardiomyocyte mRNA-spe-
cific reagent(s) will be labeled with a detectable marker 
(such as a fluorescent dye), or be modified to facilitate 
detection. In other embodiments, the cardiomyocyte mRNA 
or molecular beacon-specific reagent will not be directly 60 
labeled or modified. 
Unless stated otherwise as apparent from the following 
discussion, it will be appreciated that terms such as "detect-
ing," "receiving," "quantifying," "generating," "register-
ing," "determining," "obtaining," "processing," "comput-
ing," "deriving," "estimating," "calculating" "inferring" or 
the like may refer to the actions and processes of a computer 
The instructions relating to the use of the kit for carrying 
out the disclosure generally describe how the contents of the 
kit are used to carry out the methods of the disclosure. 
Instructions may include information as sample require-
ments (e.g., form, pre-assay processing, and size), steps to 
design molecular beacons, steps to introduce molecular 
system, or similar electronic computing device, that manipu-
lates and transforms data represented as physical (e.g., 
electronic) quantities within the computer system's registers 
65 and memories into other data similarly represented as physi-
cal quantities within the computer system memories or 
registers or other such information storage, transmission or 
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display devices. Embodiments of the methods described 
herein may be implemented using computer software. If 
written in a programming language conforming to a recog-
nized standard, sequences of instructions designed to imple-
ment the methods may be compiled for execution on a 
variety of hardware platforms and for interface to a variety 
of operating systems. In addition, embodiments are not 
described with reference to any particular programming 
language. It will be appreciated that a variety of program-
ming languages may be used to implement embodiments of 10 
the disclosure. 
It is to be further understood that, because some compo-
nents and method steps may be implemented in software, the 
actual connections between the systems components (or the 
process steps) may differ depending upon the manner in 15 
which the disclosure is programmed. Given the teachings of 
the disclosure provided herein, one of ordinary skill in the 
related art will be able to contemplate these and similar 
implementations or configurations of the disclosure. 
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phore at one end and a quencher at the other end. MBs are 
designed to form a stem-loop (hairpin) structure in the 
absence of a complementary target so that fluorescence of 
the fluorophore is quenched; however, hybridization with 
the target mRNA opens the hairpin and separates the reporter 
from the quencher, which allows emission of a fluorescence 
signal (FIG. lB). MB technology has been tested in a variety 
of cell types to detect mRNA at various levels of expression 
and has been demonstrated to not alter the expression level 
of target genes. MBs may be used for detecting mouse 
embryonic stem cells (mESCs) by simultaneous targeting of 
intracellular Oct4 (octamer-binding transcription factor 4) 
mRNA and surface markers. 
Protocols have been developed to differentiate mouse and 
human PSCs into cardiomyocytes and devised a strategy to 
isolate cardiomyocytes by applying MBs that target cardio-
myocyte-specific mRNAs, followed by FACS (FIG. 2). One 
can purifying cardiomyocytes at high efficiency and speci-
ficity from hPSC differentiation cultures with this clinically 
compatible purification system. These purified cardiomyo-
cytes are functional in vitro and in vivo. 
The following Examples are provided to illustrate the 20 
disclosure, but are not intended to limit the scope of the 
disclosure in any way. Five MBs were synthesized by MWG Operon using 
standard resin-based synthesis methods with HPLC purifi-
25 cation (Table 1 ). Examples 
Purification of Cardiomyocytes from Differentiating 
Pluripotent Stem Cells Using Molecular Beacons 
that Target Cardiomyocyte-Specific mRNA 
Although methods for generating cardiomyocytes from 
pluripotent stem cells have been reported, current methods 
produce heterogeneous mixtures of cardiomyocytes and 
noncardiomyocyte cells. Here, pluripotent stem cell-derived 
cardiomyocytes are purified by cardiomyocyte-specific 
molecular beacons (MBs ). MBs are nucleic acid probes that 
emit a fluorescence signal when hybridized to target 
mRNAs. MBs targeting mRNAs of either cardiac troponin T 
30 
35 
or myosin heavy chain 6/7 were generated. Among MBs, an 
MB that targeted myosin heavy chain 6/7 mRNA (MHCl-
MB) identified up to 99% ofHL-1 cardiomyocytes, a mouse 
cardiomyocyte cell line, but <3% of 4 noncardiomyocyte 
cell types in flow cytometry analysis, which indicates that 
MHCl-MB is specific for identifying cardiomyocytes. 
MHCl-MB was delivered into cardiomyogenically differ-
entiated pluripotent stem cells through NUCLEOFEC-
TION®. The detection rate of cardiomyocytes was similar to 
the percentages of cardiac troponin T- or cardiac troponin 
I-positive cardiomyocytes, which supports the specificity of 
MBs. MHCl-MB-positive cells were sorted by fluores-
cence-activated cell sorter from mouse and human pluripo- 50 
tent stem cell differentiating cultures, and about 97% cells 
expressed cardiac troponin T or cardiac troponin I as deter-
mined by flow cytometry. These MB-based sorted cells 
maintained their cardiomyocyte characteristics, which was 
verified by spontaneous beating, electrophysiological stud- 55 
ies, and expression of cardiac proteins. When transplanted in 
40 
45 
a myocardial infarction model, MB-based purified cardio-
myocytes improved cardiac function and demonstrated sig-
nificant engraftment for 4 weeks without forming tumors. 
A strategy was developed to purify cardiomyocytes from 60 
differentiating PSCs by targeting genes that are specifically 
expressed in cardiomyocytes. Molecular beacons (MBs) 
hybridized to cardiomyocyte-specific mRNAs enable isola-
tion of cardiomyocytes from a mixed population. This 
method can be applied for both basic research and clinical 65 
applications. FIG. lA shows MBs that are dual-labeled 
antisense oligonucleotide nanoscale probes with a fluoro-
TABLE 1 
List of Molecular Beacons and Parameters 
Beacon Target Beacon 
Name Sequence Sequence 
TN Tl CCCAAGATCCCC- TACCCTCTCTCCATC-
GATGGAGAGAG GGGGATCTTGGGTA 
(SEQ ID NO. 9) (SEQ ID NO. 14) 
TNT2 AGAACCGCCTGG- CCCTCTCTTCAGCCA-
CTGAAGAGA GGCGGTTCTGAGGG 
(SEQ ID NO. 10) (SEQ ID NO. 15) 
TNT3 GAACAGGAGGAA- ATCCTCAGCCTTCCT-
GGCTGAGG CCTGTTCGAGGAT 
(SEQ ID NO. 11) (SEQ ID NO. 16) 
MHCl GTGAAGAAGAAG- CCTCCATCTTCTTCT-
ATGGAGG TCACGGAGG 
(SEQ ID NO. 12) (SEQ ID NO. 3) 
MHC2 AAGAGCCGGGAC- TTGGCACCAATGTCC-
ATTGGTGCCAA CGGCTCTTGCCAA 
(SEQ ID NO. 13) (SEQ ID NO. 17) 
In silica description of the molecular beacons synthesized 
for study. The duplex melting temperature describes a mea-
sure of the predicted affinity between the sequence-specific 
beacon loop and the target sequence. MHCl indicates myo-
sin heavy chain 1; MHC2, myosin heavy chain 2; TNT!, 
troponin T 1; TNT2, troponin T 2; and TNT3, troponin T 3. 
In Beacon Sequence, italic letters indicate stem sequences. 
An efficient method for purifying cardiomyocytes from 
differentiating mouse and human PSCs by directly targeting 
the mRNA of cardiomyocyte-specific genes is provided 
herein. Using a MB that targeted the mRNA of MYH6 and 
MYH7 followed by FACS, one is able to enrich a population 
made up of >97% cardiomyocytes from differentiating 
PSCs. Their identity as cardiomyocytes was verified by a 
series of experiments that included flow cytometry, immu-
nocytochemistry, and qRT-PCR. Importantly, these purified 
cardiomyocytes displayed spontaneous beating on further 
culture and demonstrated stable action potentials and Ca2+ 
oscillation in electrophysiological studies. When injected 
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into infarcted heart, MB-purified cardiomyocytes were inte-
grated and survived robustly for 4 weeks in post-MI hearts, 
showing improved cardiac function without forming tumors. 
On the other hand, mice injected with unpurified cardio-
myocytes developed teratomas. These results support the 
idea that MB-based isolated cardiomyocytes are pure and 
functionally intact cardiomyocytes and that cardiomyocyte 
purification is important for cell therapy. 
Despite continuous improvements in current cardiomyo-
cyte differentiation protocols, the resulting differentiated cell 
populations still contain a percentage of noncardiomyocytes. 
Hence, one of the major challenges is to develop stable 
isolation techniques that allow scalable purification of car-
diomyocytes. Recently, studies using FACS-based cardio-
myocyte purification have attracted attention. In the first, a 
mitochondrial dye, TMRM, was suggested to be useful for 
cardiomyocyte selection, enriching up 99% of cardiomyo-
cytes as determined by the expression of Acnt2 (a-sarcom-
eric actinin) in immunocytochemistry. This approach was 
based on findings that cardiomyocytes have high mitochon-
drial content and can be purified via fluorescent dyes that 
label mitochondria. However, other subsequent studies dem-
onstrated that TMRM not only failed to identify immature 
cardiomyocytes early in differentiation culture but also 
detected noncardiogenic cells or undifferentiated hESCs, 
because these cells take up significant amounts of TMRM. 
In addition, independent studies reported the identification 
of surface marker proteins, SIRPA and VCAM-1, and sug-
gested their utility for isolating cardiomyocytes from differ-
entiating hPSCs. To identify a candidate protein, a panel of 
370 known commercially available antibodies were 
screened. SIRPA was identified as a specific marker for 
cardiomyocytes differentiating from hPSCs. Subsequently, 
isolation via FACS with an antibody against SIRPA enriched 
cardiac precursors and cardiomyocytes from hPSCs, yield-
ing up to 98% TNNT2+ cells. However, SIRPA+ cells 
expressed significant amounts of smooth muscle marker 
genes such as ACTA2 and CNN! and an endothelial cell 
gene, CD34, which brings into question the utility of SIRPA 
as a sole marker for cardiomyocyte isolation. There are 
variations in the yield of cardiogenic marker expression 
(NKX2-5) after further culture of sorted SIRPA+ cells, 
reaching as low as 2.8% cardiomyocytes depending on the 
isolation time and duration of culture. Furthermore, NKX2-
5+ cells did not express SIRPA, which raised concerns about 
specificity and sensitivity ofSIRPA. Thus, VCAMl, through 
a transcriptome analysis and used it as an additional marker 
to isolate cardiomyocytes. However, FACS with both SIRPA 
and VCAMl antibodies was only able to enrich cardiomyo-
cytes that ranged from 55% to 95% in purity. Moreover, 
because both proteins are known to be expressed in other 
cell types, the possibility of contamination with noncardio-
myocyte cells even after purification with SIRPA and 
VCAMl may be an issue. 
The MB-based cardiomyocyte purification strategy has a 
number of unique advantages. First, by directly targeting 
specific intracellular mRNA, there is no need to make 
extensive efforts to identify surface proteins for cell isolation 
with the corresponding antibodies. Second, MB-based cell 
purification minimizes contamination of other cells by using 
MBs designed to hybridize with unique sequences in the 
mRNAs of interest specifically expressed in the target cell 
type. Although significant efforts have been made to identify 
SIRPA and VCAMl as cell-surface markers for cardiomyo-
cytes, both SIRPA and VCAMl are expressed in other 
organs such as brain and lung, which raises questions about 
the utility of these surface markers in a range of differen-
24 
tiation systems. Another advantage of the MB-based puri-
fication method is its application to any species. It allows 
expansion of the research scope with any desired cells. 
Because SIRPA is not highly expressed in the mouse, its 
usage is limited to human cells. In contrast, the MB-based 
method allows isolation of virtually any cell because of the 
unlimited accessibility of MBs to intracellular mRNA. 
Therefore, in addition to cardiomyocytes, the MB-based 
sorting technique described here can be broadly applied to 
10 the isolation of other cell types, such as neural-lineage cells 
or islet cells, which are elements in regenerative medicine 
but do not have specific surface proteins identified to date. 
The present cell transplantation study provides an impor-
tant insight into the need for purified cardiomyocytes for 
15 cardiac cell therapy. An unexpectedly high rate of tumors 
developed in mice that received unpurified mESC-derived 
cardiomyocytes. Although unpurified, these cells were dif-
ferentiated into the cardiac lineage, and about 50% of cells 
were cardiomyocytes. To date, a few studies have reported 
20 syngeneic or allogeneic transplantation of unpurified mESC-
derived cardiomyocytes into infarcted heart, and all dem-
onstrated tumor formation in hearts. The present disclosure 
demonstrated that purified cardiomyocytes do not form 
tumors, and this purification process is a prerequisite for 
25 cardiac cell therapy with PSCs. Similar cardiac cell therapy 
studies were conducted with hPSC-derived cardiomyocytes, 
and many of them showed functional improvement with no 
tumor formation, albeit using nonpurified cells. 
To ensure that MBs were safe and effective to use in target 
30 cells, several experiments were performed to determine cell 
viability and functionality immediately and several days 
after delivery of MBs. MBs were minimally disruptive, 
because the results did not differ significantly between hPSC 
cardiomyocytes and control cells in the assays performed. 
35 MBs usually degrade within an hour, so cell viability or cell 
fate change is not a serious concern. In addition, to confirm 
their specificity, extensive testing was performed to ensure 
that the MB signal was a robust indicator of cardiomyocytes 
based on the binding of the probe to MYH6/7. The MBs 
40 were tested in solution with synthetic target oligonucleotides 
that varied from the ideal sequences by 6 bp, the closest that 
a BLAST search through the human transcriptome pre-
dicted. None of the MBs used in the present study increased 
their fluorescence by >50% even when incubated with 
45 excess target sequence. 
The purified hPSC-derived cardiomyocytes sorted via 
MBs will be enormously useful for clinical applications and 
preclinical studies. A major obstacle to the use of cells 
differentiated from hPSCs for clinical applications is poten-
50 tial tumorigenicity or aberrant tissue formation after cell 
transplantation. By eliminating unwanted cells, this technol-
ogy will advance the use of hPSC-derived cardiomyocytes. 
This purification technique in combination with cardiomyo-
cytes generated from patient-specific hiPSCs will be of great 
55 value for drug screening and disease modeling, as well as 
cell therapy. 
Cardiomyocyte-Specific MB Generation 
To determine optimal candidate genes detectable by MBs, 
quantitative RT-PCR (qRT-PCR) analysis was performed on 
60 known cardiac-specific genes using mRNAs extracted from 
freshly isolated mouse adult cardiomyocytes, human neo-
natal heart tissues, and human fetal heart tissues. The 
representative cardiac structural genes cardiac troponin T 
(TNNT2, also known as cTNT) and myosin heavy chain 
65 (MYH6/7, also known as a/~MHC) were most highly 
expressed in all of these samples and thus were determined 
to be targets for MBs. On the basis of the qRT-PCR results, 
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5 MBs were designed (Table 1) that targeted unique sites in 
TNNT2 or MYH6/7 mRNA in both mouse and human using 
design rules and BLAST (Basic Local Aligmnent Search 
Tool; National Library of Medicine, Bethesda, Md.) 
searches to ensure uniqueness. These MBs were synthesized 5 
with a Cy3 fluorophore or a FAM fluorophore at the 5' end 
and a BLACK HOLE QUENCHER® 2 or a BLACK HOLE 
QUENCHER® 1 at the 3' end as specified in Table 1. The 
beacon fluorescence signal was quantified when hybridized 
on STO feeder cells were enzymatically detached to form 
embryoid bodies, which were cultured for 5 days and plated 
on a fibronectin-coated dish for cardiomyocyte differentia-
tion. After 3 to 4 days of differentiation in the presence of 
ascorbic acid (50 µg/mL), spontaneously beating clumps 
began to appear. Flow cytometry analysis demonstrated that 
the percentage ofTnnt2-positive cells was 13.4% and 47 .1 % 
at days 4 and 9, respectively (FIG. 4B). Immunostaining 
further demonstrated that cells dissociated from beating 
clumps displayed Tnnt2, Tnni3, and Actn2 (or a-sarcomeric 
actinin), which confirmed their cardiomyocyte nature (FIG. 
to perfectly complementary and mismatched targets by 10 
incubating 500 nmol/L MBs with targets of increasing 
concentrations (100-500 nmol/L). The MB signal was 
recorded with a microplate reader and normalized by the 
signal in wells with an MB only. All MBs displayed a linear 
response to increasing concentrations of complementary 15 
target and a low response to mismatched targets. 
4C). The results with mouse iPSCs were similar. After 
establishing the differentiation system, attempts were made 
to isolate cardiomyocytes from differentiating mESCs using 
MBs. The differentiating mESCs at day 9 were subjected to 
NUCLEOFECTION® with MHCl-MB and subjected to 
To determine the most efficient transfection method to 
deliver MBs into living cells, the following techniques were 
compared: Streptolysin 0, LIPOFECTAMINE® 2000, 
LULLABY®, 34 NUCLEOFECTION®, electroporation, 
and microinjection. To quantify delivery efficiency, a non-
specific MB was fabricated that has a nonspecific sequence 
with FAM dyes conjugated to both the 5' and 3' ends, which 
allows the probe to fluoresce regardless of its open or closed 
conformation. The nonspecific MB were delivered into 
various cell lines, including an immortalized mouse cardio-
myocyte cell line [HL-1cardiomyocytes24] smooth muscle 
cells, mouse embryonic fibroblasts, and mESCs. Flow 
cytometry analysis demonstrated that regardless of the cell 
type, NUCLEOFECTION® consistently delivered MBs 
into >95% of the cells, showing the highest delivery effi-
ciency. 
The sensitivity of MBs designed to target cardiomyocyte-
specific mRNAs was determined. As a positive control, 
HL-1 cardiomyocytes were used. The cardiomyocyte iden-
tity ofHL-1 cardiomyocytes were confirmed by flow cytom-
etry showing that 97.2% of cells expressed Tnnt2. Each of 
the candidate MBs targeting TNNT2 or MYH mRNA was 
delivered into HL-1 cardiomyocytes by NUCLEOFEC-
TION®, and efficacy was analyzed by flow cytometry. 
Among the 5 MBs (TNT!, TNT2, TNT3, MHCl, and 
MHC2) examined, the MB designated as MHCl-MB 
yielded the highest rate of MB-signal-positive cells (98.9%; 
FIG. 3A). 
To determine the specificity of MHCl-MB, a random-
sequence MB (random beacon) that has a 16-base target 
sequence that does not match any sequence in the mouse or 
human genome was delivered as a negative control and 
displayed negligible fluorescence in HL-1 cardiomyocytes 
(FIG. 3B), thus ruling out the possibility that the fluores-
cence signal from MHCl-MB was caused by nonspecific 
interactions or probe degradation by endonucleases. To 
further verify the specificity of the MHCl-MB, MHCl-MB 
was delivered into smooth muscle cells, mouse aortic 
endothelial cells, mouse cardiac fibroblasts, and mESCs, 
which are the cell types most likely to contaminate in 
cardiomyogenically differentiated PSC cultures. Flow 
cytometry analysis showed that <3% of these cells displayed 
a detectable fluorescence signal. These results suggest high 
sensitivity of the MHCl-MB for cardiomyocyte-lineage 
cells. 
Purification of mESC-Derived Cardiomyocytes 
Whether this MB could be useful for isolating cardio-
myocytes from differentiating mouse PSCs was investi-
gated. An embryoid body-mediated system was established 
to efficiently differentiate mESCs into cardiomyocytes (FIG. 
4A). In brief, undifferentiated mouse ESCs (Jl) maintained 
FACS. The percentage of cells positive for fluorescence 
signal from MHCl-MB was 49.2±4.8% (FIG. 4D). There 
was significant agreement between the detection rate of 
20 cardiomyocytes with antibody-based ( 47 .1 % Tnnt2-positive 
cells) and MB-based ( 49.2% MHCl-MB-positive cells) flow 
cytometry results, which supports the specificity of MHCl-
MB. Fluorescent microscopic imaging also confirmed these 
results. Next, cells were sorted by FACS with MHCl-MB, 
25 and 98.4% of the sorted MHCl-MB-positive cells exhibited 
Tnnt2 in flow cytometry (FIG. 4E). Immunocytochemistry 
verified that virtually all sorted MHCl-MB-positive cells 
expressed Tnnt2 and Actn2 (FIG. 4F). qRT-PCR analyses 
demonstrated that these sorted cells expressed 2- to 6-fold 
30 higher levels of Tnnt2, Myh6, Myh7, and Myl2 than the 
presorted cells (FIG. 4G). Genes representing other lineages 
were either expressed at negligible levels (Acta2, Ddr2, 
Gata!, and Sox17) or were undetectable (Pecaml, MyoD, 
and NeuroD) in the sorted cells (FIG. 4G). Importantly, 
35 these sorted cells showed spontaneous contraction over 2 
weeks, which suggests that these MB-based purified cardio-
myocytes were functional. 
Purification of hESC-Derived Cardiomyocytes 
The utility of MB-based cell sorting for hPSC-derived 
40 cardiomyocytes was investigated. A 4-step protocol was 
developed for differentiating hPSCs into cardiomyocytes 
(FIG. SA). In phase 1, undifferentiated hESCs (Hl) were 
directly transferred onto Matrigel-coated plates and cultured 
as a monolayer under MTESR® media (Stemcell Technolo-
45 gies, Vancouver, Canada) for cell expansion. Next, to induce 
mesodermal differentiation, several combinations of meso-
dermal inducers were tested and compared by qRT-PCR 
with mesodermal markers including T (or Brachyury) and 
KDR. A combination of bone morphogenetic protein 4 
50 (BMP4; 10 ng/mL), activinA (3 ng/mL), and basic fibroblast 
growth factor (FGF2; 5 ng/mL) was the most efficient for 
mesodermal differentiation. To induce cardiac lineage dif-
ferentiation in phase 3, different methods were tested. 
Supplementation with conditioned media produced by the 
55 mouse endodermal cell line END-2 induced the highest 
expression of cardiac lineage markers such as NKX2-5, 
TNNT2, MYH6, and MYH-7. Finally, in phase 4, continu-
ous treatment with a ~-adrenergic receptor agonist, isopro-
terenol, for as few as 4 days efficiently generated spontane-
60 ously beating cardiomyocytes. 
Flow cytometry analysis demonstrated that the percentage 
ofTNNI3-positive cells was 10.2% and 43.1 % at days 9 and 
13, respectively (FIG. SB). The MHCl-MB were delivered 
to the cardiomyogenically differentiated hESCs at day 13 in 
65 phase 4. Flow cytometry analysis showed that the percent-
age of cells positive for MHCl-MB signal was 46.3% (FIG. 
SC). These MHCl-MB-treated cells were sorted by FACS, 
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and 97.6±1.4% of the sorted MHCl-MB-positive cells 
exhibited TNNI3 expression in flow cytometry analysis 
(FIG. SD). Almost all cells showed cardiomyocyte-like 
morphology and stained positive for TNNT2 and TNNI3 by 
immunocytochemistry (FIG. SE). qRT-PCR analyses 
showed a significant increase in expression of cardiomyo-
cyte-specific genes (TNNT2, MYH6, MYH7, and MYL2) 
and a decrease in expression of genes specific for smooth 
muscle cells (calponin), fibroblasts (THYl), skeletal myo-
cytes (MYOD), neural lineage cells (NEUROD), and 
endothelial cells (PECAMl [platelet/endothelial cell adhe-
sion molecule 1 ]), which suggests enrichment of cardiomyo-
cytes and elimination of other lineage cells by cell sorting 
with the MB (FIGS. SF and SG). 
Stable action potentials were recorded from cardiomyo-
cytes that were purified via MHCl-MB and cultured for 7 to 
14 days after FACS. Three major types of action potentials 
were observed: Nodal-like (6 of 46), atrial-like (11 of 46), 
and ventricular-like (29 of 46) action potentials (FIG. SH). 
These results indicate that cells purified via a cardiomyo-
cyte-specific MB are electrophysiologically intact, func-
tional cardiomyocytes and can maintain these characteristics 
in culture. 
Purification of Cardiomyocytes from hiPSCs 
The utility of MHCl-MB for isolating cardiomyocytes 
from differentiating hiPSCs (BJl) was examined. The dif-
ferentiation system for cardiomyocytes from hESCs was 
successfully applied to hiPSCs, yielding 40.7% of TNNI3-
positive cardiomyocytes at day 13 (FIGS. 6A and 6B). 
MHCl-MB was delivered into the differentiating hiPSCs at 
day 13, and the percentage of cells positive for MHCl-MB 
as analyzed by flow cytometry was 45.5% (FIG. 6C). FACS 
based on MB signal resulted in enrichment of TNNI3-
positive cells to 97.2±1.9% (FIG. 6D). Almost all the sorted 
cells stained positive for TNNI3 or TNNT2 in immunos-
taining. qRT-PCR again showed an approximately 3- to 
7-fold increase in cardiomyocyte-specific gene expression 
and a substantial reduction or negligible levels of other 
lineage gene expression (FIG. 6E). The sorted MHCl-MB-
positive cardiomyocytes showed spontaneous contraction 
and rhythmic calcium oscillations (FIG. 6F). These data 
suggest that the MHCl-MB-based purified cardiomyocytes 
were functional cardiomyocytes. Taken together, the results 
indicate that MBs that target cardiomyocyte-specific mRNA 
28 
cardiomyocytes or PBS over the same follow-up period 
were not detected by echocardiographic or histological 
examination. Tumor formation in unpurified cardiomyocyte-
injected mice did not allow appropriate functional compari-
son between mice that received unpurified and purified 
cardiomyocytes; however, purified cardiomyocyte-injected 
mice showed a higher ejection fraction than PBS-injected 
mice (FIG. 7D), which indicates improved cardiac function. 
Immunohistochemistry for cardiac tissues injected was con-
lO ducted with purified cardiomyocytes. Confocal microscopic 
examination demonstrated that injected cardiomyocytes 
(Dil-positive) were engrafted as clusters, survived robustly 
for 4 weeks, and expressed representative cardiomyocyte 
15 proteins. Taken together, these results suggest that injected 
MB-purified cardiomyocytes are integrated into ischemic 
myocardium and are functional in vivo. 
Non-Genetic Purification of Ventricular Cardiomyocytes 
from Differentiating Embryonic Stem Cells Through 
20 Molecular Beacons Targeting a Ventricle-Specific Transcrip-
tion Factor 
Each type of cardiac chamber-specific CM has unique 
functional, structural, and electrophysiological characteris-
tics. Thus, transplantation of cardiomyogenically differen-
25 tiated cells which include heterogeneous CMs and other 
lineage cells into injured myocardium might induce dys-
rhythmia, asynchronous cardiac contraction, or aberrant 
tissue generation. It would therefore be ideal to generate a 
pure population of ventricular CMs from PSCs to be used for 
30 cardiac cell-based therapy. 
Prior studies used genetic modifications for isolating 
ventricular CMs by inserting a fluorescent reporter gene 
driven by the ventricular myosin light chain 2 (MYL2 or 
MLC-2v) promoter into mouse ESCs and embryonic carci-
35 noma cell lines. Such genetic modifications preclude clinical 
use of the cells due to concerns oftumorigenicity or adverse 
reactions. These ventricular CMs would not be appropriate 
for drug development or disease modeling either, due to the 
random and permanent changes in the genome by genetic 
40 modifications or the use of viruses. Accordingly, a transient 
biochemical method for selecting ventricular CMs is 
needed. 
in live cells allow isolation of functional cardiomyocytes 45 
from differentiating mouse and human PSCs with high 
specificity and efficiency. 
Although not surface markers, there are several genes 
specifically expressed in ventricular hearts or CMs. As a 
ventricular-specific transcription factor, Iroquois homeobox 
protein 4 (IRX4) is expressed in the ventricular myocardium 
while absent from both atria and the outflow tract. In 
addition, IRX4 positively regulates ventricular chamber-
specific gene expression by activating ventricular myosin 
heavy chain-1 (VMHCl) while suppressing atrial myosin 
heavy chain-1 (AMHCl) expression. As a structural protein, 
Engraftment and Improvement of Cardiac Function After 
Implantation of Purified Cardiomyocytes 
To determine the behavior and effects of MB-based puri- 50 
fied cardiomyocytes in ischemic myocardium, purified or 
unpurified cardiomyocytes derived from mESCs or the same 
volume of PBS was injected into the myocardium after 
induction of MI in mice. Echocardiography was performed 
weekly to measure cardiac remodeling and function. One 55 
week later, however, in the mice that received unpurified 
cardiomyocytes, a distinct mass was observed in the left 
ventricular lumen of the hearts, which grew over 4 weeks 
(FIGS. 7Aand 7B). Postmortem examination at 3 to 4 weeks 
revealed tumor masses in 11 of 12 mice. By careful gross 60 
examination, tumors invaded internally into myocardium 
and externally into the pericardium (FIGS. 7B and 7C). 
Cardiac tissues were fixed and stained with hematoxylin and 
eosin. Microscopic examination revealed that all tumors 
consisted of structures derived from all 3 embryonic germ 65 
layers, which indicates teratomas (FIG. 7C); however, 
tumors in any of the mice that received MB-based purified 
MYL2 (or MLC-2v), one of the essential MLC-2 isoforms 
that is important for the contractile function of ventricular 
CMs, is expressed in ventricular CMs. MYL2 expression is 
mostly restricted to the ventricular segment of the heart with 
minimal expression in the outflow track during cardiogen-
es1s. 
MB-mediated targeting of a.I~ myosin heavy chain 
(MYH6/7) mRNA followed by FACS sorting can allow 
purification of general CMs from mouse and human PSCs 
MBs; however, targeting transcription factor mRNAs which, 
due to their low copy numbers compared to structural 
protein mRNAs, are more challenging. By targeting Irx4 
mRNA with specific MBs, one is able to enrich functional 
ventricular CMs derived from differentiating mouse ESCs 
(FIG. 8). This is the first demonstration that transcription 
factors can be targeted for MB-based cell sorting. 
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Ventricular cardiomyocytes (CMs) are a desireable cell 
type for cardiac repair. However, without specific surface 
markers, isolation from differentiating pluripotent stem cells 
(PSCs) has been challenging. Purified ventricular CMs were 
generated from differentiating mouse embryonic stem cells 
(mESCs). Different MBs (IRX4-1, -2, -3) were designed to 
target specific regions of mRNA of iroquois homeobox 
protein 4 (Irx4 ), a specific transcription factor for ventricular 
CMs. 
30 
Its expression is restricted to the ventricles throughout the 
developmental as well as postnatal periods. 
One of these, IRX4-2 MB, showed the highest sensitivity 
and specificity and was selected to purify mESC-derived 
ventricular CMs. IRX4-2 MB was applied to cardiomyo-
genically-differentiating mESC cultures and FACS-sorted 
IRX4-2 MB-positive cells. Flow cytometry demonstrated 
that 92 to 97% of IRX4-2 MB-positive cells expressed 
cardiac troponin 2 (Tnnt2) and myosin light chain 2 ven-
tricular isoform (Myl2). Importantly, about 98% of IRX4-2 
MB-positive cells displayed ventricular CM-like action 
potentials during electrophysiological analyses. These 
IRX4-2 MB-based purified ventricular CMs continuously 
maintained their CM characteristics verified by spontaneous 
beating, Ca2+ transient, and expression of ventricular 
CM-Specific Proteins. 
As mRNAs of structural proteins are present in abundant 
copies, the likelihood of successful isolation was relatively 
high. In fact, another transcription factor, NKX2.5, was 
initially tried as a target but were not able to sufficiently label 
general CMs. In this study, the improved design technology 
enabled us to isolate ventricular CMs by targeting a tran-
scription factor. To prove the specificity in this study, 
10 
extensive assays were carried out to ensure that the MB 
signal was a precise indicator of ventricular CMs based on 
the hybridization of the probe to IRX4. MBs were tested in 
solution with synthetic target oligonucleotides that varied 
15 from the ideal sequences by 6 bp, the closest that a BLAST 
search through the mouse transcriptome allowed. However, 
a major challenge was whether the designed MBs could be 
hybridized to a sufficient quantity of target mRNA sequences 
to allow sorting of ventricular CMs. Among three designed 
20 MBs, one of them, IRX4-2 MB, was bound sufficiently to 
allow cell sorting. 
Another difficulty was to find a delivery method to deliver 
enough MBs to sufficiently label target mRNAs. Seven 
transfection methods were tested to deliver MBs into living Despite the importance of ventricular CMs for cell-based 
therapy and drug development, no studies reported isolation 25 cells, Streptolysin 0, LIPOFECTAMINE® 2000, LUL-
LABY®, electroporation, microinjection and NUCLEO-
FECTION®, and found that NUCLEOFECTION® in a 
specific buffer induced maximal target detectability with 
minimal cell toxicity. Cytotoxic effects of MB themselves 
of ventricular CMs from genetically unmodified stem cells. 
Homogeneous ventricular type CMs were generated from 
mESCs, without altering genomes, via MB based sorting for 
Irx4, a ventricular CM-specific transcription factor. This 
method yielded functional ventricular CMs with high speci-
ficity and efficiency. NUCLEOFECTION® of a selected 
MB targeting mRNA of Irx4 followed by FACS sorting 
enabled enrichment of ventricular type CMs to 92% from 
differentiating mESCs. These purified CMs demonstrated 
ventricular CM-like action potentials at at 98% and Ca2+ 35 
oscillations in electrophysiological studies, suggesting func-
tionally intact ventricular CMs. These cells showed coordi-
nated contraction and survived more than 2 weeks in culture 
while maintaining their phenotype. 
30 within the cells were reported negligible. MBs degrade 
within a few hours in the cells so that their effects on cell 
Reported CM differentiation protocols generate heteroge- 40 
neous CMs mixed with other cell populations. Several 
recent studies reported non-genetic methods for isolating 
general CMs. However, these protocols still generate het-
erogeneous CMs, not chamber-specific CMs. Given the 
major role of ventricular CMs for cardiac contractile func- 45 
tion, there is a need to develop a non-genetic method to 
isolate ventricular CMs from differentiating PSCs, which 
will be of value to many preclinical and clinical applications. 
viability or cell identity are low. Even with repetitive trans-
fections of MBs, we did not observe phenotypic or func-
tional changes, as evidenced by unaffected spontaneous 
contraction and immunocytochemistry assays. 
This production of homogeneous and functional PSC-
derived ventricular CMs using non-transgenic approach will 
yield new avenues for clinical and research applications. 
First, a pure population of ventricular CMs generated by this 
method offers a safer and effective option for cell therapy 
and tissue engineering. The mixed populations of PSC 
derived CMs are more likely to cause abnormal electrical 
activity or less efficient contractile function. From a research 
perspective, the MB-purified ventricular CMs represent a 
powerful in vitro tool for disease investigation and drug 
discovery. They could be used for better defined in vitro 
cardiac disease models for genetic or idiopathic cardiac 
diseases such as long QT syndrome. They can also serve as 
an in vitro model to test chamber specific effects of cardiac 
drugs. These purified CMs will yield more accurate genetic 
and epigenetic information through high throughput 
sequencing techniques. This MB-mediated cell sorting 
method can be applied for isolating other cardiac cells such 
as nodal cells or atrial CMs. 
Studies reported isolation of ventricular CMs derived 
from transgenic mESCs or embryonic carcinoma cell lines. 50 
For example, ventricular CMs were isolated from geneti-
cally modified mESCs in which a fluorescence reporter gene 
was driven by a promoter of Myl2. While useful for basic 
research, these genetic methods cannot be used for clinical 
applications or disease modeling due to genetic modifica-
tions. Cell sorting with specific surface markers is a pre-
ferred method for isolating target cells from PSC cultures. 
However, no unique surface markers are known for ven-
tricular CMs, and to identify and validate such markers and 
develop antibodies would require considerable resources. 
55 Ventricular Cardiomyocyte-Specific Gene Selection Gen-
eration of IRX4 MBs 
Irx4 was selected as a target gene for generating ventricu-
lar CM-specific MBs. First, mRNAexpression levels oflrx4 
was measured via quantitative RTPCR (qRT-PCR) analysis 
60 in CMs isolated from either ventricles or atria of mouse adult 
Directly targeting intracellular mRNAs of ventricular 
CM-specific genes is a solution. This approach avoids 
genetic modifications and the need to identify specific 
surface markers. Irx4, which is a more specific identifier of 
ventricular CMs than Myl2. Irx4 plays a role in regulating 65 
chamber-specific gene expression in the developing heart 
and is involved in determining ventricular cell specification. 
hearts. Myl2, a ventricular CM-specific gene, was measured 
as a positive control. The results showed that Irx4 is robustly 
expressed in ventricular CMs but not atrial CMs. The 
expression levels of both Irx4 and Myl2 mRNAs were 
substantially higher in mouse ventricular CMs compared to 
atrial CMs, indicating that Irx4 is a viable target for MB 
selection. 
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IRX4 MBs were designed targeting distinct sites on the 
mouse Irx4 mRNA. In addition, mFold and the RNA Com-
poser Webserver were used to model our IRX4 MBs and to 
predict binding site availability in the target mRNAs. These 
IRX4 MBs were synthesized with a Cy3 fluorophore on the 5 
5' end and a BLACK HOLE QUENCHER® 2 on the 3' end 
express IRX4, by NUCLEOFECTION®. The cells were 
analyzed for false-positive signals using flow cytometry. 
Among the three MBs (IRX4-1, -2, and -3) examined, the 
MBs designated as IRX4-1 and IRX4-2 yielded significantly 
lower rates of MB-positive cells on mEFs (IRX4-1: 
0.9±0.1 %, and IRX4-2: 1.4±0.1 %). In contrast, IRX4-3 
displayed a high percentage of false-positive signals (IRX4-
3: 40.6±3.8%) in mEFs. Hence both IRX4-1 and IRX4-2 
were selected for further experiments. Next, to evaluate the 
as specified in Table 2. 
TABLE 2 
The list of IRX-4 MBs. 
Beacon 
Name 
IRX4-1 
IRX4-2 
IRX4-3 
IRX4-4 
Beacon 
sequence 
CACCTAGTTTT-
GTTATATTAGC-
CTCCCTAGGTG 
(SEQ ID NO. 
18) 
CCCTGACGTAA-
ACTTTATGCTT-
CAGGG 
(SEQ ID NO. 
1) 
CAGGCAGAGAG-
TAGAAAGCAGA-
TGCCTG 
(SEQ ID NO. 
19) 
CAGGCAGAGAG-
TAGAAAGCAGA-
TGCCTG 
(SEQ ID NO. 
19) 
Control ACGACGCGACA-
MB AGCGCACCGAT-
ACGTCGT 
(SEQ ID NO. 
20) 
Target 
sequence 
AGGGAGGCT-
AATATAACA-
AAAC 
(SEQ ID NO. 
21) 
CCCTGAAGC-
ATAAAGTTT-
A CG TC 
(SEQ ID NO. 
22) 
AGGCATCTG-
CTTTCTACT-
CTCTG 
(SEQ ID NO. 
23) 
AGGCATCTG-
CTTTCTACT-
CTCTG 
(SEQ ID NO. 
23) 
GTATCGGTG-
CGCTTGTCG-
CG 
(SEQ ID NO. 
24) 
Dye 
Cy3 
Cy3 
Cy3 
Alexa 
488 
Cy3 
Quencher 
BHQ2 
BHQ2 
BHQ2 
BHQl 
BHQ2 
MB fluorescence signals were quantified when hybridized 
to perfectly complementary or mismatched synthetic targets 
by incubating 500 nM MB solution with targets of increas-
ing concentrations (60-500 nM). IRX4 MB signals were 
recorded using a microplate reader and normalized to the 
signals in wells with beacon only. IRX4 MBs displayed a 
linear response to increasing concentrations of complemen-
tary targets and a low response to mismatched targets. 
Delivery of MBs into the Cells Selection of Optimal IRX4 
MB for Identifying Ventricular-Like Cardiomyocytes 
After attempting several different delivery methods for 
transfection of MBs, we found that NUCLEOFECTION® 
with NUCLEOFECTION® Solution V and program A033 
(Lonza) was an efficient method to deliver MBs to a variety 
10 sensitivity of the two candidate MBs (IRX4-1, and -2), each 
of the candidate IRX4 MBs was delivered into mouse 
neonatal ventricular CMs and analyzed with flow cytometry. 
IRX4-2 MB identified a substantially higher percentage of 
ventricular CMs (85.8±3.7%) compared to IRX4-1 MB 
15 (17.9±2.1%). Based on these results, IRX4-2 MB was used 
as a final candidate for enriching the mESC-derived ven-
tricular CMs (FIG. 9B). 
IRX4-2 MB was examined with HL-1 CMs, an immor-
talized mouse atrial CM cell line known to retain atrial CM 
20 characteristics. The results from flow cytometry analysis 
demonstrated that less than 2% of HL-1 CMs displayed 
positive signals for IRX4-2 MBs, further supporting their 
specificity for ventricular CMs (FIG. 9C). IRX4-2 MBs 
were tested the against mouse smooth muscle cells (SMCs), 
25 mouse aortic endothelial cells (mECs), mouse cardiac fibro-
blasts (mCFs) and mESCs, which are the most likely con-
taminating cell types in cardiomyogenically differentiated 
PSC cultures. Flow cytometry analysis showed that fewer 
than 3% of those cells displayed detectable fluorescence 
30 signals. These results indicate that IRX4-2 MB is specific for 
identifying ventricular CMs. 
Generation of Ventricular CMs from Mouse Embryonic 
Stem Cells 
To ensure stable production ofmESC-derived ventricular 
35 CMs, an embryoid body (EB)-mediated CM differentiation 
system was established (FIG. lOA). Undifferentiated mouse 
ESCs (Jl) maintained on STO feeder cells were enzymati-
cally detached to form EBs. Since EB-induced differentia-
tion alone is not sufficient for producing a high percentage 
40 of CMs, day-4 EBs were plated into a fibronectin-coated 
dish and added ascorbic acid (50 µg/ml) to enhance CM 
differentiation. Spontaneously beating clumps began to 
appear 3-4 days after plating. After 7 days of CM differen-
tiation on monolayer cultures, the cells were enzymatically 
45 dissociated. They were applied to a discontinuous Percoll 
gradient (40.5% to 58.5%) to enrich mESC-derived CMs. 
Percoll mediated-separation typically produces three layers 
of cells and the bottom layer includes a higher percentage of 
CMs. Thus, the cells in the bottom layer were collected and 
50 cultured for another 7 days in the presence of cyclosporine 
A (30 µg/ml) to further induce CM differentiation. IRX4 
MBs were applied to these 18-day cultured mESC-derived 
CMs. 
of cell types. To further refine this system, we also designed 
two distinct MBs to act as controls. A non-specific interac- 55 
tion indicator MB (RQ) contains a random 20 bp loop 
sequence which is not similar to any known RNA in mouse 
cells, so any fluorescence would indicate an undesirable 
mechanism. A confirmation of delivery control MB (UQ) 
used the same random sequence but does not contain a 60 
quencher so that it fluoresces at all times. Both MBs were 
delivered to cells to ensure that transfection was efficient and 
that MB signal was specific to the targeted sequence. 
qRT-PCR analyses revealed dynamic changes in the 
expression of CM-specific genes in this differentiation sys-
tem indicative of efficient CM differentiation. Expression of 
cardiac contractile genes (Tnnt2 and Myh7), and genes for 
atrial (Mlc2a), and ventricular CMs (Myl2 and Irx4) began 
to appear 7 days after culture. Expression of Myl2 and Irx4 
continuously increased until day 18 (FIG. lOB). 
Immunocytochemistry and flow cytometry were carried 
out to further characterize the cell population at day 18. 
Immunocytochemistry demonstrated that day 18 cells sig-
nificantly expressed CM-specific proteins including ACTN2 The specificity, sensitivity and reliability of each IRX4 
MB was examined in separate systems. To determine the 
specificity of MBs, each of the IRX4 MBs were delivered 
into mouse embryonic fibroblasts (mEFs), which do not 
65 (a-sarcomeric actinin), TNNT2 (cardiac troponin T), and 
MYH6/7 (a and~ myosin heavy chain) confirming their CM 
nature. A substantial number of cells which were positive for 
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ACTN2, TNNT2 and MYH6/7 concomitantly expressed 
MYL2 (or MLC2V) which is a specific protein for ventricu-
lar CMs. Flow cytometry analyses showed that the percent-
age of TNNT2 and MYL2 positive cells were 67.9±4.5% 
and 39.2±3.8%, respectively (FIG. 4D). These results indi- 5 
cate efficient generation of CMs with a significant percent-
age of ventricular CMs through our CM differentiation 
system. 
34 
transient. Collectively, these results indicate that the major-
ity of the enriched IRX4-2 MB positive cells were function-
ally intact ventricular CMs. 
Cellular Characterization of FACS-Sorted Ventricular CMs 
To examine the cardiac identity and homogeneity of the 
ventricular CMs purified with IRX4-2 MB, immunocyto-
chemistry was conducted with antibodies against various 
CM specific markers (ACTN2, TNNT2 and MYH6/7 and 
MYL2) and ventricular CM marker (MYL2) 2-3 days after Purification of mESC-Derived Ventricular-Like CMs 
Through IRX4-2 MBs 10 FACS sorting and cultures. Immunocytochemistry demon-
strated that almost all IRX4-2-based enriched ventricular 
CMs exhibited ACTN2, TNNT2, and MYH6/7. Further-
more, a positive immunoreactivity for MYL2 was found in 
After establishing the CM differentiation system, IRX4-2 
MB was delivered to the 18-day differentiated cells to isolate 
ventricular-like CMs (FIG. 11). Apre-validated NUCLEO-
FECTION® protocol was used to deliver the MB and 
FACS-sort the cells (FIG. llA). Flow cytometry results 15 
showed that 41.3±5.8% of cells were positive for IRX4-2 
MB fluorescence signal (FIG. llB). This number is similar 
to the detection rate of ventricular CMs using antibody 
based (39.2% ofMyl2-positive cells) methods. FACS-sort-
ing for IRX4-2 MB was conducted and the MB-positive 20 
CMs were seeded onto fibronectin coated plates for further 
experiments. The IRX4-2 MB-positive CMs began to beat 
spontaneously within 48 hrs and continued to beat vigor-
ously for up to two weeks. Only a small number of cells beat 
in the IRX4-2 MB-negative plate. 1-3 days after FACS 25 
sorting, flow cytometry analyses was conducted using 
TNNT2 and MYL2 antibodies to quantify the percentage of 
CMs and ventricular-like CMs in IRX4-2-MB positive cells. 
Almost all sorted IRX4-2 MB-positive cells expressed 
TNNT2 and MYL2 (TNNT2: 97.2%±3.4% and MYL2: 30 
91.6±5 .1 % ) indicating efficient enrichment of mESC-de-
rived ventricular CMs by IRX4-2-MB sorting (FIG. llC). 
Electrophysiological Characteristics of Ventricular-Like 
CMs Through IRX4 MB 
To investigate the electrophysiological characteristics of 35 
IRX4-2 MB-purified ventricular CMs, whole-cell patch 
clamp analyses was performed (FIG. 12A). It is known that 
electrophysiological characteristics of ventricular or atrial 
CMs are distinct. In primary adult CMs, average action 
potential duration (APD) of ventricular CMs is significantly 40 
longer than APDs of atrial CMs. The primary CMs in fetal 
stage showed similar patterns of APD at 90% ofrepolariza-
tion (APD90; ventricular CMs: 140±7 ms vs. atrial CMs: 
95±7 ms). In addition, CMs derived from mESCs displayed 
similar differences in electrophysiological characteristics 45 
between ventricular CM (APD50: 99.3±15.9 ms, APD90: 
151.4±22.1 ms) and atrial (APD50: 20.7±7.2 ms, APD90: 
60.6±17 ms)38. The APD50 of IRX4-2-MB positive and 
negative CMs were 159±21.7 ms and 35±7.8 ms, respec-
tively (P<0.01). Furthermore, the average upstroke slope of 50 
IRX4-2-MB positive and negative CMs were 251±43.7 and 
126.7±51.9 mV/ms, respectively (P<0.01) (FIG. 12B). 
Based on these results, 98% of IRX4-2 MB-positive cells 
possessed ventricular-type APs ( 49 out of 50 cells) whereas 
atrial or nodal-type APs were not observed. Approximately 55 
24% of IRX4-2 MB-negative cells exhibited an atrial-like 
AP (12 out of 50 cells) (FIG. 12C). 
To determine the contractile properties of IRX4-2 MB-
based sorted CMs, we performed real-time intracellular 
calcium imaging analysis. FIG. 12D shows a two-dimen- 60 
sional scan of an enriched ventricular CM loaded with Fluo. 
all of the IRX4-2 MB-positive ventricular CMs. Importantly, 
these IRX4-2 MB-positive ventricular CMs abundantly 
expressed GJAl (known as connexin 43), an important 
connexin isoform in the formation of gap junctions between 
ventricular CMs, indicating that these enriched ventricular 
CMs possess the functional capability of forming cardiac 
junctions. qRT-PCR analyses further demonstrated that 
expression of ventricular CM genes Irx4 and Myl2 as well 
as general CM genes were substantially enriched in IRX4 
MB-positive cells compared to the IRX4 MB-negative cell 
population (FIG. 13). Furthermore, these IRX4 MB-positive 
cells showed a significant increase in expression of general 
CM-specific genes (Tnnt2, and Myh6/7) compared to the 
IRX4 MB-negative cells (FIG. 13). Genes representing atrial 
specific CMs (Myl7) or other cell types were either 
expressed at negligible levels (Acta2, Ddr2, and MyoD) or 
were non-detectable (Pecaml, and Neuro D) in the IRX4 
MB-positive cells (FIG. 13). Taken together, the data indi-
cates that IRX4-2 MBs that target ventricular CM-specific 
mRNA in live cells allow isolation of functional ventricular 
CMs from differentiating mESCs with high specificity and 
efficiency. 
Isolation of any Cell from Differentiating Human Mixtures 
Using Molecular Beacons 
Cardiomyocytes (CMs) derived from pluripotent stem 
cells (PSCs ), including embryonic stem cells (ESCs) and 
induced pluripotent stem cells (iPSCs), are a source for 
regenerating damaged cardiac tissues. In addition, the PSC-
derived CMs are useful for modeling genetic diseases such 
as long QT syndrome 1 (LQTl) and drug testing for various 
cardiac diseases. PSC-derived CMs possess a clear cardiac 
phenotype displaying spontaneous contractile activity, car-
diac-type mechanisms of excitation-contraction coupling, 
and expression of expected sarcomeric proteins, ion chan-
nels, and transcription factors. Transplantation of PSC 
derived CMs into rodent models induced cardiac repair 
through enhancement of cardiac function. 
Although the following protocol is focused on the isola-
tion of CMs from differentiating human PSCs, it can be 
applied to the isolation of CMs from mouse PSCs with 
minimal alterations. There are five elements of the MB 
isolation protocol to consider for isolation of specific cells 
types from differentiating PSCs: (1) identification of specific 
mRNAs that are highly and uniquely expressed in the 
specific cells types; (2) design and validation of MBs 
targeting cell-specific mRNAs with high signal-to-back-
ground ratio; (3) delivery ofMBs into a mixed population of 
cells from differentiating PSCs with high efficiency and 
throughput; (4) high-throughput isolation of the target cells 
with FACS based on MB signal; (5) validation of specific 
cell type characteristics using electrophysiology and immu-
Spontaneous calcium transients were recorded in the upper 
panel, where increasing calcium is indicated by the change 
in color from dark blue to light blue, and fluorescence 
intensity is normalized to the baseline measured at time 0 
(Fo ). Average calcium intensity along each point of the line 
is shown in the lower panel indicating a cyclic calcium 
65 nocytochemistry. Although the experimental design 
described here is focused on the isolation of CMs, the 
MB-based method is quite general and can be readily 
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modified for the isolation and enrichment of other cell types 
by designing MBs to target the specific gene(s) highly 
expressed in the particular cell type. 
In order to use MBs to isolate specific cells from a mixed 
cell population, target mRNAs that are highly and uniquely 5 
expressed in the cell type of interest should be identified. 
These mRNAs should to have a relatively high abundance so 
that, when MBs are hybridized to their mRNA target in the 
specific cells (such as CMs ), the resulting fluorescence 
signal is at least 5-fold higher than that in other cell types. 10 
Genes encoding structural proteins involved in the contrac-
tile process are the most logical choice for CMs. However, 
for isolating other cell types it typically requires that the 
gene expression profiles are quantified using qRT-PCR (or 
DNAmicroarray) to identify specific mRNAs that have high 15 
levels (> 10 fold) compared with that in other cell types in the 
mixed cell population in the PSC differentiation culture. It is 
important to choose multiple target genes highly expressed 
36 
cells, but conventional methods may result in low cell 
viability. Recent advances in electroporation technology 
(such as NUCLEOFECTION®) have led to a reduction in 
the harmful events, including heat generation, metal ion 
dissolution, pH variation, and oxide formation. The 
advanced electroporation methods could lead to cellular 
internalization of oligonucleotide probes with high transfec-
tion efficiency (>90%) and high cell viability (>80%). Using 
NUCLEOFECTION®, it is possible to uniformly deliver 
MBs into millions of cells within 20 min. 
One particular issue is to make sure that the difference in 
MB signal in the mixed cell population, especially that 
between CMs and other cell types is not an artifact due to 
delivery preferential uptake of MBs by a specific cell type. 
It is therefore important to ensure that cells in the mixed 
population take up beacons MBs uniformly. To this end, the 
random-sequence MB is modified to have two identical 
fluorophores instead of a dye-quencher pair (FIG. 14C) and in the cell type of interest so that at least one mRNA would 
be specific enough and result in high MB signal. 
Once CM-specific genes are identified, MBs can be 
designed by targeting regions of the corresponding mRNA 
where excellent probe accessibility and signal specificity can 
20 used as a positive-control probe for delivery studies. After 
probe delivery into differentiating cells, fluorescence signals 
are quantified and a relatively uniform signal distribution is 
expected. This experiment is designed to confirm that the 
be achieved. The target sequences of a specific mRNA may 
not be accessible due to secondary structure of the mRNA or 25 
RNA-binding proteins. To enhance target accessibility, an 
RNA secondary structure prediction program (e.g., mFOLD) 
can be used to identify potential single-stranded regions of 
the mRNA. It is also important to select target sequences 
with a sufficient (35%-65%) GC content so that MBs so 30 
designed would have a good affinity to their targets. Finally, 
NCBI BLAST search is typically performed to identify 
unique sequences of the mRNA for MBs to target (target 
sequences), and to minimize the number of sequences that 
differ from a target sequence by only a few ( <5) bases. Since 35 
it is impossible to accurately predict target accessibility in 
living cells, multiple (3 three to five-5) candidate MBs are 
usually designed and tested for against a specific mRNA. 
An important issue with the MB-based approach is signal 
specificity. Ideally, MBs delivered into a mixed cell popu- 40 
lation exhibit a high level of signal only in CMs but not in 
other cell types due to the high expression of the target gene 
MB signal specificity is due to MB hybridization to target 
mRNAs rather than MBs preferentially entering one cell 
type. 
To ensure that a high purity CM population is isolated 
from differentiating PSCs, MB-positive cells should be 
tested to ascertain that (i) they highly express CM-specific 
genes and (ii) they have low (or zero) expression levels of 
genes associated with other cell lineages. CM specific mark-
ers such as TNNT2, TNNI3, MYH6/7, and MYL2 can be 
analyzed in the MB-positive population using both RT-PCR 
and immunocytochemistry to yield both population-based 
results and quantitative information on the number of cells 
expressing specific markers. It is also important to demon-
strate that the MB-positive cells do not express genes that 
are markers of other cell types, including skeletal muscle, 
neural progenitor cells, fibroblasts and endothelial cells. To 
ensure that the MB-positive cells represent a high purity 
population of CMs, a high percentage of cells expressing 
CM specific markers and a low percentage of cells express-
ing markers indicating other cell lineages are required. 
It should be noted that MBs are suitable for the detection 
of abundantly expressed mRNAs and should be delivered to 
cells and analyzed very rapidly. While MBs do increase their 
fluorescent intensity by an order of magnitude upon binding 
their complementary target, cells take up between 2,000 and 
20,000 MB per transfection. In order to yield a 2 to 1 
increase in fluorescent intensity, the number of transcripts 
are typically therefore approximately 10% of the number of 
MB delivered, e.g. at least 200 copies per cell. In addition, 
MB should be delivered to cells quickly because of the 
inherently short functional lifespan of exogenous nucleic 
in CM cells. However, in certain cases, a high level of 
non-specific signal from MBs may occur due to delivery, 
MB degradation, or MB-protein interactions in cells. To 45 
determine MB signal specificity, a negative-control random 
MB was designed whose probe sequence does not match 
with any mRNA sequence in the mouse or human genome. 
Any signal from the random MBs after delivery into HL-1 
cells (a cell-line derived from mouse atrial CMs) would be 50 
non-specific background signal. The ratio of MB signal from 
CM-specific mRNA and background signal from random 
MB gives the signal-to-background ratio, S/N. To have high 
signal specificity, a well-designed the MB should have a 
S/N>5 in CMs. 55 acid sequences in a cellular environment. We have therefore 
used NUCLEOFECTION® to deliver MB to the cytoplasm 
of large numbers of cells and MB signals are detected or 
measured in less than 4 hours to avoid potential artifact. This 
makes MB ideal for secreted or structural proteins. 
There are several MB delivery methods, including the use 
of microinjection, cell penetration peptides (CCPs), strep-
tolysin 0 (SLO), and electroporation. Microinjection is 
low-throughput, and often interferes with normal cell func-
tion. Although the CCP- or SLO-based delivery of MBs 
could have high efficiency and throughput, the delivery 
efficiency is typically cell-type dependent, so it may not 
work for the mixed cell population resulting from PSC 
differentiation. Further, when using CCPs or SLO for MB 
delivery, MBs might be trapped in endosomes and degraded 65 
there, causing a high level of background signal. Electropo-
ration has been used to deliver oligonucleotides into living 
60 Protocol for Preparing of High-Purity Cells (Cardiomyo-
cytes) from Differentiating Pluripotent Stem Cells Using 
Molecular Beacons 
Steps 1-7: CM specific-MB Design Considerations 
Timing-I 0 days 
Step 1: Identify CM-specific genes. Identify genes highly 
expressed in CMs such as cardiac troponin T (cTNnT) and 
al~ myosin heavy chain (MYH6/7) based on literature 
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search. Check if these genes are also highly expressed in 
other cell types in the mixed cell population during PSC 
differentiation. 
Step 2: Confirm high gene expression levels using qRT-
PCR. Using at least 100,000 cells from the specific cell 5 
population and prepare total RNA with the RNEASY® mini 
plus kit according to the manufacturer's instructions. Con-
vert the RNA into cDNA using the iScript cDNA synthesis 
kit from BioRad. Perform either TAQMAN® or SYBR® 
Green real-time PCR using a 7500 Fast Real-Time PCR 10 
system. Run all annealing steps at 60° C. Normalize all 
target genes to GAPDH in multiplexed reactions performed 
in triplicate. Calculate differences in CT values (llCT=CT 
gene of interest-CT GAPDH in experimental samples) for 
each target mRNA by subtracting the mean value ofGAPDH 15 
(relative expression=2-llCT). 
Step 3: Predict the secondary structure of the target 
mRNA. Enter the sequence into a secondary structure pre-
diction program (e.g., mFOLD) to generate best guesses for 
single stranded regions so that MBs would have good 20 
accessibility to the target sequence. 
Step 4: Design the MB loop region. Identify a sequence 
of 15-30 bases of the target mRNA predicted to be single 
stranded. Select a region with 35%-65% GC content, and 
design a complementary sequence with a predicted melting 25 
temperature (Tm) of 60° C. in 150 mM NaCl when hybrid-
izes to the target mRNA. This sequence (the reverse comple-
ment of the target sequence) will form the loop of the MB. 
Step 5: Add the stems onto the MB loop. Add a stem to 
the loop sequence by appending complementary arms of 5 30 
bases long to the 3' and 5' end of the loop sequence 
respectively. MBs with a total length of more than 40 bases 
may form a secondary structure therefore should be avoided. 
It may be desirable to add only one arm with a 5-base 
sequence complementary to the loop sequence on the oppos- 35 
ing end in order to create a shorter MB (shared-stem MB). 
A 5-base stem with a GC content of -60% should be strong 
enough to generate a stem-loop hairpin structure with a Tm 
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MWG Operon or IDT, where HPLC purification of the MBs 
to eliminate the free dye is performed. To determine MB 
performance, the synthetic target oligonucleotide (usually 
single strand DNA) with the same sequence as target 
mRNA, and mutant (mismatched) oligonucleotide should 
also be ordered for MB characterization in solution. MBs 
with DNA backbones are sufficient for CM isolation. It may 
be important to design and test several CM-specific MBs 
which can be ordered simultaneously to reduce wait times. 
Resuspend all oligonucleotides in nuclease-free, 0.1 xTE, pH 
7.0 buffer at 100 µM to make stock solutions. Avoid freeze-
thaw cycles to preserve stability and function ofMBs. Pause 
point: MB can be stored at -20° C. or -80° C. for up to 6 
months after synthesis. 
Steps 8-10 MB Validation in Solution 
Timing-2 hours 
Step 8: Design and test several CM-specific MBs hybrid-
izing to different sequences of the target mRNA. Use 
Optimem or a similar buffer to make a 500 µL aliquot of 1 
µM CM-specific MB. In separate tubes use the same buffer 
to dilute the target oligonucleotide and mismatched oligo-
nucleotide to 1.5 µM. Make serial dilutions of the target 
oligonucleotide and the mismatched oligonucleotide to 
establish dose dependence. 
Step 9: Mix solutions in a 384 well black-bottomed plate. 
Add 25 µL of MB solution to each well of a 384-well 
black-bottomed plate, then add 25 µL of each concentration 
of the solutions containing target oligonucleotide or mis-
matched oligonucleotide to their designated wells. Include 
one blank well and one well with DNAse 1 as negative and 
positive controls, respectively. 
Step 10: Analyze the fluorescence intensity ofMBs using 
a microplate reader. Establish a dose dependence curve 
using the serial dilutions of the target oligonucleotide. The 
MB signal at the highest target oligonucleotide concentra-
tion is generally between 5 and 30 times higher than the 
background signal quantified in the negative control experi-
ment in which the signal level of MBs without any target is of -50° C. Do not use Guanine for the first 3 bases at the 5' 
end due to its tendency to quench fluorophores. 
Step 6: Use in silica analysis to avoid foreseeable errors 
in MB design. Use the NCBI BLAST search tool to identify 
other mRNAs that the MB may hybridize to in the cell type 
of interest. Use the MB sequence as input. The closest match 
should be the targeted mRNA sequence from Step 4, and the 
second closest match should have at least 4 base pairs 
mismatch compared with the mRNA target sequence. For 
the validation step, test both the MB formed using the 
mRNA target sequence and the control MB (mutant MB, see 
FIG. 14D) formed using the second closest sequence (mis-
matched sequence) from the Blast search. 
40 measured. The MB signal in the well with the highest 
concentration of mismatched oligonucleotide should be no 
more than 1.5 times the background signal. Candidate MBs 
that do not meet these conditions should be disregard due to 
lack of specificity and low S/N. MBs that satisfy these 
Step 7: Select the fluorophore-quencher pair and order the 
MB and oligonucleotide targets. Steps 1-6 identify three 
oligonucleotide sequences, a MB with its loop and stem 
sequences, the target sequence, and a mismatch (mutant) 
sequence. To form the MB, select a dye-quencher pair and 
conjugate the dye and quencher to the 5' and 3' ends of the 
MB sequence respectively. The most affordable options are 
the Fam fluorophore with BLACK HOLE QUENCHER® 1 
or the Cy3 fluorophore with BLACK HOLE QUENCHER® 
2. Use the Cy3 dye for experiments where another molecule 
is taking up the FITC/GFP wavelengths. Attach the quencher 
to 3' end to ensure that all MBs will have a quencher even 
if the fluorophore is not conjugated to the MB due to a 
synthesis error. For labs without an oligonucleotide synthe-
sizer facility, it is recommended to order MBs from one of 
the many high quality oligonucleotide providers such as 
45 conditions are selected for further testing. 
If no MB meets these conditions, MBs should be rede-
signed. If the MBs highly fluoresce in the presence of a 
mismatched oligonucleotide, increasing the stem length by 
adding a basepair may solve the problem. If the MBs do not 
50 fluoresce at all in the presence of the target oligonucleotide, 
weaken the stem by removing a basepair from the stem or 
changing a C-G pair to an A-T pair in the stem. 
Steps 11-12: MB delivery testing with mouse embryonic 
fibroblasts (MEF) NUCLEOFECTION® is an electropora-
55 tion method for transferring nucleic acids such as DNA and 
RNA molecules into cells. Under typical NUCLEOFEC-
TION® conditions, MBs are delivered into both the cell 
cytoplasm and the cell nucleus. Since the target mRNAs are 
only in the cell cytoplasm, MBs delivered into the cell 
60 nucleus should result in a very low background signal. To 
check the efficiency of MB delivery via NUCLEOFEC-
TION® and select optimal delivery conditions, a delivery 
control MB (FIG. 14C) is designed which has a non-specific, 
'random' sequence with two FAM dyes conjugated to both 
65 5' and 3' ends, allowing the probe to fluoresce without any 
target when delivered into MEF cells using NUCLEOFEC-
TION®. Timing-I day 
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Step 11: Deliver positive control MBs into a control cell 
line using NUCLEOFECTION®. Plate MEF cells at 
50-60% confluency in DMEM medium containing 10% 
vol/vol FBS and culture them overnight at 37° C. Add the 
delivery control MB (FIG. 14C) to the NUCLEOFEC- 5 
TION® solution to reach 500 nM MB concentration. Detach 
40 
expressed in non-CM cells but CM-specific MBs fluoresce 
in these cells, more specific MBs should to be designed and 
tested to avoid the non-specific signals. 
Step 16: Select the final CM-specific MBs. Repeat steps 
13-15 to select the final MB designs which result in high 
fluoresce signal in positive control cells (such as HL-1) 
AND and very low background fluoresce signal in negative 
control cells (such as non-CM cells). These MBs will be 
used for further study for the isolation of hPSC-derived 
10 CMs. In most of the cases, one CM-specific MB that has 
satisfactory performance (high positive signal and low back-
ground signal) would be sufficient. 
one million cells per condition, wash with PBS, and resus-
pend in the NUCLEOFECTION® solution containing deliv-
ery control MBs. Use a gentle centrifugation of 90 g for 10 
minutes to avoid damaging the cells. Perform NUCLEO-
FECTION® using a variety of programs to identify the 
optimal program with the highest uniform delivery effi-
ciency. Immediately after NUCLEOFECTION®, gently 
pipette cells from the cuvette into cell culture medium and 
keep them there for at least 10 minutes. Ensure that all PBS 15 
is removed from the solution to avoid diluting the electropo-
ration solution. 
Step 17-20 Stem Cell Differentiation 
Timing-2-3 weeks 
Step 17: Culturing undifferentiated hPSCs. Culture hPSCs 
on mitotically inactivated MEF (STO) cells in DMEM/F12 
supplemented with 20% serum replacement, 1 % L-gluta-
mine, 1 % nonessential amino acids, 100 mM ~-mercap­
toethanol, and 4 ng/ml basic fibroblast growth factor. 
Step 12: Analyze cells using flow cytometry. After MB 
delivery, gently centrifuge the cells at 90 g's for 10 minutes, 
then aspirate the media. Resuspend the cells in PBS and 
analyze the cells using any standard flow cytometer. For 
flow cytometry assays, first run an untransfected sample. 
Use this non-fluorescent sample to set the lower limits of 
gates which can be used to detect MB positive cells. 
20 Change the medium every day and transfer hPSCs to new 
feeder cells every 5 to 7 days. Culture cells for at least 1 
passage after thaw before beginning differentiation. 
Step 18: Begin 2D hPSC differentiation. Dissociate undif-
ferentiated hPSCs to small clusters (10-20 cells) by treat-
A high percentage of cells should display high fluores-
cence signal from the delivery control MBs after MB 
delivery. If fewer than 80% of the cells are positive for MB 
signal (MB-positive), continue to test other electroporation 
parameters to increase the transfection rate, repeating steps 
25 ment with Dispase (1 mg/ml) and directly transfer them onto 
growth factor reduced Matrigel-coated plates as a two 
dimensional culture. Culture the cells for 24-48 hrs in 
MTESR® media (STEM CELL Technologies) for their 
10 and 11 until a satisfactory percentage (e.g., >80%) of 30 
MB-positive cells is achieved. 
Steps 13-15 MB specificity testing in HL-1 CMs and 
non-CM cells as positive and negative controls, respectively 
Timing-I day 
Step 13: Deliver MBs into HL-1 CM cells using 35 
NUCLEOFECTION®. Use the optimized NUCLEOFEC-
TION® parameters and the procedure described in Step 11 
to deliver the CM-specific MBs designed and tested in Steps 
8-10 into HL-1 cells, which should result in a strong 
fluorescent signal. Then deliver the random sequence, nega- 40 
tive control MB (FIG. 14C) into a separate aliquot of HL-1 
cells to ensure that the false positive signal resulting from 
non-specific opening of the random MB is low. 
expansion. 
Step 19: Induce mesodermal differentiation. Incubate 
cells in media with a combination of BMP4 (10 ng/ml), 
Activin A (3 ng/ml) and FGF2 ( 5 ng/ml) for 2 days. Remove 
the cytokine media and add END-2 conditioned media 
produced by mouse endodermal cell line END-2 for 4 days. 
Step 20: Supplementation with Isoprotereneol to produce 
mature CMs. Remove conditioned media and incubate cells 
with the media containing isoproterenol (10 µM), a ~-adren­
ergic receptor agonist, for at least 4 days to generate spon-
taneously beating CMs. 
Alternatively, prepare CMs differentiated from hPSCs 
using any of the previously validated protocols, see below: 
Laflanime et al., Cardiomyocytes derived from human 
embryonic stem cells in pro-survival factors enhance func-
tion of infarcted rat hearts. Nat Biotech 25, 1015-1024 
(2007) 
Yang et al., Human cardiovascular progenitor cells 
develop from a KDR+ embryonic-stem-cell-derived popu-
lation. Nature 453, 524-528 (2008) 
Step 14: Deliver CM-specific MBs into non-CM cells 
using NUCLEOFECTION®. Deliver the CM-specific MBs 45 
into non-CM cells (such as smooth muscle cells, aortic 
endothelial cells and cardiac fibroblasts) typically present in 
the differentiating PSCs. Use the optimized NUCLEOFEC-
TION® parameters and the procedure described in Step 11; 
the MB signals in these cells should be low. 
Step 15: Analyze all cells after MB delivery using flow 
cytometry. After MB delivery, incubate cells for 10 min at 
37° C., gently centrifuge the cells at 90 g's for 10 minutes, 
then aspirate the media. Resuspend the cells in PBS and 
analyze the cells using any standard flow cytometer. Use 55 
negative control cells to set the gates as in Step 12. 
Lian et al., Robust cardiomyocyte differentiation from 
50 human pluripotent stem cells via temporal modulation of 
canonical Wnt signaling. Proceedings of the National Acad-
emy of Sciences, 2012, (10.1073/pnas.1200250109). 
The flow cytometry analysis should be performed within 
2 hours of MB delivery into the cells. Several groups have 
shown that non-specific MB signal may increase quickly -2 
hours after MB delivery due to MB degradation, resulting in 60 
a high level of false positives in flow cytometry analysis. 
If any of the CM-specific MBs generates low fluorescent 
signal from HL-1 CMs or produces a high level of false 
positive signal from non-CM cells, Steps 1-10 should to be 
repeated to identify a better CM-specific MB. In addition, 65 
double check that the non-CM cell types do not express the 
target gene(s) using qRT-PCR. If the target gene is not 
Boheler et al., Differentiation of Pluripotent Embryonic 
Stem Cells Into Cardiomyocytes. Circulation Research, 
2002, 91, 189-201 
Steps 21-25 Deliver MBs into differentiating hPSCs for 
the isolation of CMs Timing-6 hours 
Step 21: Deliver control MBs in the differentiated cells 
using NUCLEOFECTION®. Detach one million cells from 
differentiating hPSCs obtained from steps 17-20 using 
Accutase, wash with PBS, and resuspend in the NUCLEO-
FECTION® solution containing 500 nM of delivery control 
MBs. Use the optimal NUCLEOFECTION® program iden-
tified to deliver MBs into the mixed cell population. Use a 
gentle centrifugation of 90 g for 10 minutes to avoid 
damaging the cells. Immediately after NUCLEOFEC-
TION®, gently pipette cells from the cuvette into the 
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DMEM/F12 medium containing 10% vol/vol FBS and incu-
bate cells for 30 minutes at 37° C. 
Step 22: Analyze signal from delivery control MB in cells 
using a flow cytometer. Gently centrifuge the cells at 90 g's 
for 10 minutes, then aspirate the media. Resuspend the cells 5 
in PBS and analyze the cells using any standard flow 
cytometer. Cells in the mixed cell population should show 
uniform, high fluorescence signal. Use negative control cells 
to set the gates as in Step 12. 
If the signal level is low or the fluorescence signal has a 10 
high variation in different cell types, repeat Steps 11-12 to 
identify the optimal NUCLEOFECTION® program. 
Step 23: Deliver CM-specific MBs into differentiating 
hPSCs using NUCLEOFECTION®. Detach one million 
cells from differentiating hPSCs generated from steps 17-20 15 
using Accutase, wash with PBS, and resuspend in the 
NUCLEOFECTION® solution containing 500 nM of CM-
specific MBs. Use the optimal NUCLEOFECTION® pro-
gram identified to deliver MBs into the mixed cell popula-
tion. Use a gentle centrifugation of 90 g for 10 minutes to 20 
avoid damaging the cells. Immediately after NUCLEOFEC-
TION®, gently pipette cells from the cuvette into at least 1 
mL of DMEM/F12 medium containing 10% vol/vol FBS 
and incubate the cells for 10 minutes at 37° C. 
Step 24: Analyze cells using a flow cytometer. Gently 25 
centrifuge the cells at 90 g's for 10 minutes, then aspirate the 
media. Resuspend the cells in PBS and analyze the cells 
using any standard flow cytometer. Use negative control 
cells to set the gates as in Step 12. 
If none of the cell types (especially CMs) in the mixed cell 30 
population has a high level of MB signal, the target mRNA 
may be inaccessible or underexpressed. Check the expres-
sion level of the target gene in the mixed cell population 
with qRT-PCR. If the target gene is highly expressed in the 
cells from differentiating PSCs and MBs do not fluoresce, 35 
redesign MBs to target a different region of the target mRNA 
to improve MB accessibility. 
Step 25: Sort cells using fluorescence activated cell sorter. 
Gently centrifuge the cells at 90 g's for 10 minutes, then 
aspirate the media. Resuspend in PBS and sort the MB- 40 
positive cells using a cell sorter such as the FACS ARIA II® 
or a JAZZ® system. Use slightly more stringent gating 
conditions than in the previous analysis (Step 24) to ensure 
high purity of isolated CM cells. Plate cells on appropriate 
dishes (MEA plates, 6 well dishes, etc) in the DMEM/F12 45 
media containing 10% vol/vol FBS and incubate for 24-28 
hours for subsequent CM characterization assays. 
Steps 26-28 Characterize CMs purified with CM-specific 
MBs 
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formaldehyde for 10 min at room temperature. Wash cells 
twice with PBS and permeabilize them with 0.1 or 0.5% 
Triton X-100 in PBS for 10 min. Block with 1 % BSA in PBS 
for 60 min at room temperature and then incubate cells with 
either anti-ACTN2 (1:100), mouse anti-TNNT2 (1:100), or 
rabbit anti-cTnI (1:100) at 4° C. overnight. Wash the cells 
three times with 1 % Tween 20 in PBS and incubate with 
anti-mouse IgG-Alexa Fluor 594 (1:1000) or anti-rabbit 
IgG-Alexa Fluor 488 (1: 1000) in PBS for 1 h at room 
temperature. Counterstain the nuclei with DAPI. Visualize 
the samples using a fluorescent microscope or confocal laser 
scanning microscope. Alternatively, cells can be detached at 
the beginning of this procedure and analyzed using a flow 
cytometer. 
Step 28: Characterization of sorted CMs by intracellular 
flow cytometry based on the expression of cTNT. Wash the 
MB-positive cells three times with PBS and centrifuge at 
600 g for 5 min at RT. Fix the cells with 2% (wt/vol) PFA 
for 20 min at room temperature. Wash the cells two times 
with PBS and centrifuge at 600 g for 5 min at room 
temperature. Gently resuspend the cell pellets to the per-
meabilization buffer containing 5% (vol/vol) FBS and 0.5% 
(vol/vol) saponin, and incubate for 20 min for permeabili-
zation. Prepare the primary antibodies, mouse anti-cTNT, in 
staining buffer with 0.2% saponin, and add them in the tube 
with a final antibody dilution of 1: 100 for cTNT. Incubate 
overnight at 4 ° C. Wash the cells three times with staining 
buffer and centrifuge at 600 g for 5 min at room temperature. 
Resuspend the cell pellets in staining buffer with saponin 
with a 1:200 dilution of secondary antibody, Cy3 goat 
anti-mouse (Jackson). Incubate the suspensions for 1 hr min 
at room temperature. Wash the cells three times with staining 
buffer and centrifuge at 600 g for 5 min at room temperature. 
Resuspend the cells in 100 µl of PBS with 2% (vol/vol) FBS 
to quantify cTNT positive cells by flow cytometry. 
Maintain the samples in the dark by covering them with 
aluminum foil after the addition of secondary antibody. 
Steps 29-30: Measure action potential in purified CMs 
Step 29: Plate cells and prepare the cell culture on a 
microscope compatible slide. Transfer the MB-positive cells 
onto 0.1 % fibronectin-coated glass bottom microwell dishes 
and culture them for 7 days. Mount the 35-mm dishes on an 
inverted microscope and heat the stage to 37° C. with a 
heating/cooling bath temperature controller. Perfuse the 
cells with Tyrode's solution. 
Step 30: Characterize sorted CMs by action potential 
measurement. Record intracellular membrane potential 
using the EPC 7 amplifier in current clamp mode at 37±0.5° 
C. Impale individual cells with the sharp microelectrodes 
Timing-2 days 50 and record the action potential signals. Analyze action 
potentials using the Origin 6.0 software. Step 26: RT-PCR of sorted CMs. Using at least 100,000 
cells from Step 25, prepare total RNA with the RNEASY® 
mini plus kit according to the manufacturer's instructions. 
Convert the RNA into cDNA using the iScript cDNA 
synthesis kit from BioRad. Perform either TAQMAN® or 55 
SYBR® Green real-time PCR using a 7500 Fast Real-Time 
PCR system. Run all annealing steps at 60° C. Normalize all 
target genes to GAPDH in multiplexed reactions performed 
Cell Culture 
HL-1 CMs, a cell line derived from adult mouse atria50, 
was received from Dr. William Claycomb (Louisiana State 
University, New Orleans, La., USA). The HL-1 CMs were 
plated in a dish coated with 12.5 µg/ml fibronectin (Sigma) 
and 0.02% gelatin (Sigma), and maintained in complete 
Claycomb medium (Sigma) supplemented with 100 µM 
norepinephrine (Sigma), 0.3 mM L-ascorbic acid (Sigma), 4 
mM L-glutamine (Gibco) and 10% FBS (Sigma) in a 5% 
C02 atmosphere at 37° C. 
Mouse ESC Culture and Differentiation 
in triplicate. Calculate differences in CT values (llCT=CT 
gene of interest-CT GAPDH in experimental samples) for 60 
each target mRNA by subtracting the mean value ofGAPDH 
(relative expression=2-llCT). It is recommended to test at 
least 3 genes from each potential lineage (CM, fibroblast, 
neural, etc.). The specific group of genes may vary depend-
ing on the MB target gene. 
The mESCs (Jl) were maintained in high glucose Dul-
becco's Modified Eagle Medium (DMEM) supplemented 
65 with 10% FBS (Atlanta Biologicals), 1% non-essential 
amino acids solution, 1 % L-glutamine, 0.1 mM ~-mercap­
toethanol, 1 % penicillin/streptomycin and 2,000 U mL- 1 
Step 27: Immunocytochemistry of sorted CMs. Rinse the 
MB-positive cells with PBS then fix them using 4% para-
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mouse LIF (Millipore) on feeder layers of mitotically inac-
tivated STO cells (ATCC), a cell line of mouse embryonic 
fibroblasts. Prior to differentiation, mESCs were passaged 
twice on gelatin-coated dishes to remove the STO cells. 
To differentiate mESCs into cardiac lineage, an embryoid 5 
body (EB) method was employed. EBs were formed by 
suspending the cells at 107 cells/mL in 10 mL of differen-
tiation media; alpha-modified Eagle medium ( aMEM; Invit-
rogen) supplemented with 15% FBS, 1% non-essential 
amino acids, 1 % L-glutamine, 1 % ~-mercaptoethanol, 10 
L-ascorbic acid (50 µg/ml; Sigma), and 1 % penicillin/ 
streptomycin. By day 1, cells aggregated to form EBs. 
Differentiation medium was changed every day. 5 days after 
initiation of EB formation, floating EBs were enzymatically 15 
dissociated by treatment with Accutase (e-bioscience) and 
were transferred into fibronectin-coated plates. These EB-
dissociated cells were cultured in non-serum culture 
medium: DMEM/F12 (Invitrogen) supplemented with nor-
epinephrine (100 µM)) and L-ascorbic acid (50 µg/ml) for 20 
further differentiation into CMs. Typically, beating cells 
appeared on day 7. 
Human PSC Culture and Differentiation 
44 
after 2 hours at 37° C. with the mismatched beacons were 
not used for further testing, which excluded the MHC2 
beacon. 
Nucleofection® 
NUCLEOFECTION® was employed for delivering MBs 
into various types of live cells. 
Target cells were dissociated by treatment with Accutase 
( e-bioscience) and filtered through a 40-µm cell strainer (BD 
science) immediately before NUCLEOFECTION®. The 
dissociated cells (0.5-lx106) were carefully suspended in 
100 µl of NUCLEOFECTOR® Solution V (Lonza) main-
tained at room temperature, and 0.5 µl of 500 nM MB was 
added for each reaction. NUCLEOFECTION® was per-
formed using a NUCLEOFECTOR® II (Amaxa Biosys-
tems) set to the A033 NUCLEOFECTOR® program. After 
termination of NUCLEOFECTION®, 500 µl of cold 
DMEM/F12 media was added to the reaction cuvette and the 
contents were gently transferred into a clean tube by a 
flexible pipette (Lonza). All procedures for NUCLEOFEC-
TION® were performed inside a biological safety cabinet 
(Labconco) in the dark to prevent light induced non-specific 
reaction of MB. Subsequently, 1 ml of pre-warmed DMEM/ 
F12 media was added into each tube and further incubated 
25 in a 5% C02 atmosphere at 37° C. for 10 min for MB 
Undifferentiated hPSCs including both hESCs and hiP-
SCs were cultured on mitotically inactivated STO cells in 
DMEM/F12 supplemented with 20% serum replacement 
(Invitrogen), 1 % L-glutamine, 1 % nonessential amino acids, 
100 mM ~-mercaptoethanol, and 4 ng/ml basic fibroblast 
growth factor (bFGF; R & D systems). The medium was 
changed every day and the hPSCs were transferred to new 30 
feeder cells every 5 to 7 days. To direct the differentiation of 
hPSCs to the cardiac lineage, we designed a staged protocol 
that is divided into four distinct phases. In phase 1, undif-
ferentiated hPSCs were dissociated to small clusters (10-20 35 
cells) by treatment with Dispase (1 mg/ml; Invitrogen) and 
directly transferred onto growth factor reduced Matrigel 
(BD Biosciences)-coated plates as a two dimensional cul-
ture. These cells were cultured for 24-48 hrs in MTESR® 
media (Stem cell technology) for their expansion. Next, in 40 
phase 2, to induce the expanded hPSCs into mesodermal 
lineage, a combination of BMP4 (10 ng/ml), Activin A (3 
ng/ml) and FGF2 (5 ng/ml) was added for 2 days. In phase 
3, differentiating hPSCs were cultured in END-2 condi-
tioned media for 4 days. To produce END-2 conditioned 45 
media, mouse endodermal cell line END-2 cells (gift from 
Dr Christine Mummery) were cultured in DMEM/F12 
media supplemented with 1 % Insulin-Transferrin-Selenium 
(ITS; Invitrogen), 1 % penicillin-streptomycin, and 0.1 mM 
8-mercaptoethanol at a seeding density of 5.0xl 04 cells/cm2 50 
in 0.1% gelatin coated T-75 flasks (Fisher Scientific). After 
3 days of culture, the supernatant was collected, filter-
sterilized through a 0.22-µm filter (Nalgene) and stored at 
-80° C. until further use. Finally, in phase 4, continuous 
treatment with DDadrenergic receptor agonist isoproterenol 55 
(10 µM) for as short as 4 days efficiently generated sponta-
neously beating CMs. 
Molecular Beacon Synthesis and Characterization 
Five MBs were synthesized by MWG Operon using 
standard resin-based synthesis methods with HPLC purifi- 60 
cation to ensure purity. Beacons were re-suspended in nucle-
ase free TE buffer, pH 8.0 to maximize beacon stability. 
Beacons were tested against synthetic 20-30 by complemen-
tary sequences in PBS solution to verify their activity. To 
demonstrate specificity, beacons were also tested against 65 
synthetic targets with 6 by mismatches. Any beacons show-
ing an increase in signal to noise ratio of more than 50% 
reaction. 
Flow Cytometry 
After NUCLEOFECTION®, cells were centrifuged at 
2000 rpm for 2 min, re-suspended in DMEM/F12 basal 
media, and maintained on ice for 20 min to recover. Cells 
were then analyzed by C6 Flow Cytometer (BD Biosci-
ences) or sorted using a BD FACSARIAII® cell sorter (BD 
Biosciences). Beacon signal was recorded using a 561 nm 
laser with a 585/15 nm emission filter to optimally excite 
and detect Cy3. Data were analyzed using Flow Jo software 
(Treestar ). 
RT-PCR 
Total RNA was prepared with the RNEASY® mini plus 
kit (QIAGEN) according to the manufacturer's instructions. 
The extracted RNA (100 ng to 1 mg) was reverse transcribed 
into cDNA (reverse transcription) via TAQMAN® reverse 
transcription reagents including random hexamers, oligo 
(dT), and MultiScribe™ MuLV reverse transcriptase (Ap-
plied Biosystems). qPCR was performed on a 7500 Fast 
Real-Time PCR system (Applied Biosystems) using Fast 
SYBR Green master mix (Applied Biosystems). All anneal-
ing steps were carried out at 60° C. Relative mRNA expres-
sion of target genes was calculated with the comparative CT 
method. All target genes were normalized to GAPDH in 
multiplexed reactions performed in triplicate. Differences in 
CT values (llCT=CT gene of interest-CT GAPDH in experi-
mental samples) were calculated for each target mRNA by 
subtracting the mean value of GAPDH (relative expres-
sion=2-ACT). 
Immunocytochemistry 
Cells were fixed with 4% PFA for 10 min at room 
temperature, washed twice with PBS, and permeabilized 
with 0.1 % Triton X-100 in PBS for 10 min. Cells were then 
blocked with 1 % BSA in PBS for 60 min at room tempera-
ture and incubated with anti-ACTN2 (Sigma; 1: 100), mouse 
anti-TNNT2 (NeoMarkers; 1:100), or rabbit anti-cTnI (Ab-
eam; 1: 100) at 4 ° C. overnight. The cells were washed three 
times with 1 % Tween 20 in PBS and incubated with anti-
mouse IgG-Alexa Fluor 594 (Invitrogen; 1:1000) or anti-
rabbit IgG-Alexa Fluor 488 (Invotrogen; 1: 1000) in PBS for 
1 h at room temperature. DAPI was used for nuclear 
staining. The samples were visualized under a fluorescent 
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microscope (Nikon) and a Zeiss LSM 510 Meta confocal 
laser scanning microscope and LSM 510 Image software 
(CLSM, Carl Zeiss). 
Intracellular Ca+2 Measurement 
MB purified cells were loaded with 5 µM Quest Fluo-4 
(ABD Bioquest, Inc. Sunnyvale, Calif.) for 15 min in 5% 
C02 atmosphere. Fluo-4 fluorescence was measured every 
16 msec with a back-thinned electron multiplier CCD cam-
era (IMAGEM®; Hamamatsu Photonics, Hamamatsu, 
Japan). Four consecutive images were averaged. Ratio (Fl/ 10 
FO) to an image at minimum fluorescence intensity (FO) was 
calculated after background subtraction. The measurements 
were carried out at room temperature. 
46 
incubated in 5% C02 at 37° C. for 20 min in Tyrode's 
solution containing calcium dye, Fluo-4AM (7 µM, Molecu-
lar Probes, Eugene Oreg.). Cells on coverslips were 
mounted onto an FHD IonOptix (Ionoptix Scientific Instru-
ments, Milton Mass.) chamber between two platinum elec-
trodes placed 5 mm apart. Cells were perfused with Tyrodes 
solution at 37° C. for 30 min before imaging for deesteri-
fication of the dye. Cells were paced by field stimulation 
through the platinum electrodes with a 10 ms duration pulse 
at 0.5 Hz (HSE stimulator P, Hugo Sachs Electronik, F. R. 
Germany) Confocal imaging was performed using an Olym-
pus FV-1000 system coupled to an Olympus IX-81 auto-
mated inverted microscope (Olympus) equipped with a 40x 
water immersion lens (NA=l.15). Line scan images were 
Intracellular Ca+2 Imaging 
For calcium (Ca2+) imaging, MB-based purified cells 
were plated on 25 mm square glass coverslips (Corning) and 
15 taken for determining calcium transients ([Ca2+]) and plot-
ted as FIFO where FO was the baseline fluorescence mea-
<160> NUMBER OF SEQ ID NOS, 24 
<210> SEQ ID NO 1 
<211> LENGTH, 27 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
SEQUENCE LISTING 
<223> OTHER INFORMATION, synthetic 
<400> SEQUENCE, 1 
ccctgacgta aactttatgc ttcaggg 
<210> SEQ ID NO 2 
<211> LENGTH, 15 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic 
<400> SEQUENCE, 2 
cgtaaacttt atgct 
<210> SEQ ID NO 3 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic 
<400> SEQUENCE, 3 
cctccatctt cttcttcacg gagg 
<210> SEQ ID NO 4 
<211> LENGTH, 14 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic 
<400> SEQUENCE, 4 
atcttcttct tcac 
<210> SEQ ID NO 5 
<211> LENGTH, 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic 
sured prior to field stimulation. 
27 
15 
24 
14 
<400> SEQUENCE, 5 
ccctga 
<210> SEQ ID NO 
<211> LENGTH, 
<212> TYPE, DNA 
47 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic 
<400> SEQUENCE, 
tcaggg 
<210> SEQ ID NO 7 
<211> LENGTH, 5 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic 
<400> SEQUENCE, 7 
cctcc 
<210> SEQ ID NO 8 
<211> LENGTH, 5 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic 
<400> SEQUENCE, 8 
ggagg 
<210> SEQ ID NO 9 
<211> LENGTH, 23 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic 
<400> SEQUENCE, 9 
cccaagatcc ccgatggaga gag 
<210> SEQ ID NO 10 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic 
<400> SEQUENCE, 10 
agaaccgcct ggctgaagag a 
<210> SEQ ID NO 11 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic 
<400> SEQUENCE, 11 
gaacaggagg aaggctgagg 
<210> SEQ ID NO 12 
US 9,493,742 B2 
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-continued 
5 
5 
23 
21 
20 
<211> LENGTH, 19 
<212> TYPE, DNA 
49 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic 
<400> SEQUENCE, 12 
gtgaagaaga agatggagg 
<210> SEQ ID NO 13 
<211> LENGTH, 23 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic 
<400> SEQUENCE, 13 
aagagccggg acattggtgc caa 
<210> SEQ ID NO 14 
<211> LENGTH, 29 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic 
<400> SEQUENCE, 14 
taccctctct ccatcgggga tcttgggta 
<210> SEQ ID NO 15 
<211> LENGTH, 29 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic 
<400> SEQUENCE, 15 
ccctctcttc agccaggcgg ttctgaggg 
<210> SEQ ID NO 16 
<211> LENGTH, 28 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic 
<400> SEQUENCE, 16 
atcctcagcc ttcctcctgt tcgaggat 
<210> SEQ ID NO 17 
<211> LENGTH, 28 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic 
<400> SEQUENCE, 17 
ttggcaccaa tgtcccggct cttgccaa 
<210> SEQ ID NO 18 
<211> LENGTH, 33 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic 
<400> SEQUENCE, 18 
US 9,493,742 B2 
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-continued 
19 
23 
29 
29 
28 
28 
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cacctagttt tgttatatta gcctccctag gtg 
<210> SEQ ID NO 19 
<211> LENGTH, 28 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic 
<400> SEQUENCE, 19 
caggcagaga gtagaaagca gatgcctg 
<210> SEQ ID NO 20 
<211> LENGTH, 29 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic 
<400> SEQUENCE, 20 
acgacgcgac aagcgcaccg atacgtcgt 
<210> SEQ ID NO 21 
<211> LENGTH, 22 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic 
<400> SEQUENCE, 21 
agggaggcta atataacaaa ac 
<210> SEQ ID NO 22 
<211> LENGTH, 23 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic 
<400> SEQUENCE, 22 
ccctgaagca taaagtttac gtc 
<210> SEQ ID NO 23 
<211> LENGTH, 23 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic 
<400> SEQUENCE, 23 
aggcatctgc tttctactct ctg 
<210> SEQ ID NO 24 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic 
<400> SEQUENCE, 24 
gtatcggtgc gcttgtcgcg 
US 9,493,742 B2 
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-continued 
33 
28 
29 
22 
23 
23 
20 
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We claim: 
1. A method for purifying cardiomyocytes comprising, 
a) introducing a molecular beacon comprising a loop 
sequence having SEQ ID NO: 4 into a mixture of 
cardiomyocytes and pluripotent stem cells under con- 5 
ditions such that the molecular beacon hybridizes to 
mRNA in the cardiomyocytes providing molecular 
beacon bound fluorescent cardiomyocytes; and 
b) purifying the molecular beacon bound fluorescent 
cardiomyocytes by fluorescence activated cell sorting 10 
providing a purified composition of cardiomyoctyes. 
2. The method of claim 1, wherein the mixture of cardio-
myocytes and pluripotent stem cells have been differentiated 
by a method comprising: 
a) culturing undifferentiated pluripotent stem cells under 15 
conditions such that a mono layer of the undifferentiated 
stem cells is formed, 
b) applying bone morphogenetic protein 4 (BMP4), 
ActivinA, and fibroblast growth factor 2 (FGF2) to the 
undifferentiated stem cells under conditions such that 20 
cardiac linage cells are formed, and 
c) treating the cardiac linage cells with isoproterenol to 
generate spontaneous beating cardiomyocytes. 
3. The method of claim 1, wherein pluripotent stem cells 
are mammalian pluripotent stem cells. 25 
* * * * * 
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